Atezolizumab

Org: Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Los Angeles, CA, Seoul National University Hospital, Seoul, South Korea,

Abstract

BEAT-SC: A randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).

Org: National Cancer Center Hospital, Tokyo, Japan, Respiratory Medicine, Shanghai Chest Hospital, Shanghai, China, Department of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, Department of Respiratory Medicine and Infectious Disease, Niigata University Medical & Dental Hospital, Niigata, Japan, Biological Therapy Oncology, Tianjin Cancer Hospital, Tianjin, China,

Clinical trial

A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma

Status: Active (not recruiting), Estimated PCD: 2025-10-31

Clinical trial

A Phase 1b Study of Ensartinib in Combination With Platinum-Based Chemotherapy and Bevacizumab in ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Status: Active (not recruiting), Estimated PCD: 2027-09-23

Clinical trial

Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

Status: Recruiting, Estimated PCD: 2026-01-01

Clinical trial

A Phase II Open Label, Randomized Study Testing the Efficacy of Retifanlimab in Combination With Bevacizumab and Hypofractionated Radiotherapy in Patients With Recurrent GBM

Status: Not yet recruiting, Estimated PCD: 2026-11-30

Abstract

Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection.

Org: Gustave Roussy Cancer Center, Université Paris Saclay, Paris, France, Royal Free London NHS Foundation Trust, UCL Division of Surgery and Interventional Science,

Clinical trial

Randomized Phase 2 Study of Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer

Status: Recruiting, Estimated PCD: 2023-12-01

Clinical trial

A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Status: Recruiting, Estimated PCD: 2027-10-31

Abstract

Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.

Org: GEICO, Arcagy-Gineco, NSGO-CTU, SAKK, BGOG,

Abstract

MyTACTIC: Activity of targeted therapy in patients (pts) with advanced solid tumors harboring specific biomarkers.

Org: US Medical Affairs Oncology,

Abstract

Safety and preliminary efficacy of EIK1001 in combination with atezolizumab in participants with advanced solid tumors.

Org: Eikon Therapeutics, Inc.,

Abstract

Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Massachusetts General Hospital, Department of Radiation Oncology, UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA,

Abstract

Neoadjuvant chemotherapy with atezolizumab, bevacizumab, and FOLFOX for patients with unresectable colorectal liver metastases: A translational pilot study.

Org: Seoul, NA,

Abstract

RNA expression-based hypoxia score as a prognostic and predictive biomarker in hepatocellular carcinoma.

Org: JC Walter Jr Center for Transplantation and Sherrie and Alan Conover Center for Liver Disease and Transplantation,

Abstract

Genetic drivers of severe skin toxicity with immune checkpoint inhibitors (ICIs) in Asian patients.

Org: Chugai Pharmaceutical Co., Ltd.,

Abstract

Trends in prices of checkpoint inhibitors in the US, 2016-2023.

Org: Brigham and Women's Hospital, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Memorial Sloan Kettering Cancer Center,

Abstract

Early opioid exposure (EOE) and impaired efficacy in patients with advanced NSCLC treated with PD-L1 inhibition: A pooled post hoc analysis of the POPLAR and OAK trials.

Org: Division of Surgery and Cancer, Imperial College, London, United Kingdom, Campus Bio-Medico University, Rome, Italy, University Campus Bio-Medico of Rome, Roma, Italy, Institute for Research in Biomedicine, Faculty of Biomedical Sciences, Universita della Svizzera Italiana, Bellinzona, Switzerland, Evergrande Center for Immunologic Diseases, Ann Romney Center for Neurologic Diseases, Harvard Medical School and Mass General Brigham, Boston, MA,

Abstract

Multi-ethnic genome-wide association study to identify a novel locus for susceptibility to immune-related adverse events from immune checkpoint inhibitors.

Org: Department of Haematology Oncology, National University Cancer Institute Singapore, Department of Haematology-Oncology, Rheumatology Division, National University Hospital,

Abstract

Genomic landscape and therapeutic implications in advanced solid cancers: KOSMOS-II (KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors, KCSG AL-22-09).

Org: Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, National Cancer Center Hospital East, Kashiwa, Japan, Goyang-Si, South Korea, Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy,

Abstract

Standard atezolizumab leads to severe overexposure in real-world patients with lung cancer: How far could we go in extending dosing intervals and saving money?

Org: COMPO Centre de Recherche en Cancérologie de Marseille Inserm U1068 CNRS, CRCM, Hôpital Nord, SMARTc Centre de Recherche en Cancérologie de Marseille Inserm U1068, Multidisciplinary Oncology and Therapeutic Innovations,

Abstract

A phase II, multicenter, open-label study of polyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301).

Org: TreosBio,

Abstract

Preliminary results from the phase 2 study of AFM24 in combination with atezolizumab in patients with EGFR wild-type (EGFR-WT) non-small cell lung cancer (NSCLC).

Org: Janusz Korczak Provincial Specialist Hopsital, Institute of Cancer Research at the Royal Marsden, Phase 1 Clinical Trial Unit, NEXT Oncology, Hospital Universitario Quirón Salud, Early Phase Clinial Trials Unit, Maria Sklodowska-Curie National Research Institute of Oncology,

Clinical trial

PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2022-12-01

Abstract

A phase II open‐label study with atezolizumab (atezo) in combination with bevacizumab (bev) in patients (pts) with advanced chemotherapy-resistant colorectal cancer (CRC) and MSI‐like molecular signature: The MoTriColor Consortium CT3 study.

Org: Milano, MI, Italy, Napoli, Italy, Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, L?Hospitalet De Llobregat,

Clinical trial

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 3 Tiragolumab + Atezolizumab

Status: Recruiting, Estimated PCD: 2026-10-15

Clinical trial

Phase II Study of Pembrolizumab in Combination With Binimetinib and Bevacizumab in Patients With Refractory Colorectal Cancer

Status: Active (not recruiting), Estimated PCD: 2022-04-14

Abstract

A randomized, open-label phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF633/DANTE trial, a trial of AIO in collaboration with SAKK.

Org: University Cancer Center Germany, St. Anna Hospital Herne, RKH-Clinics Ludwigsburg, University Hospital Ulm, Charité-University madicine Berlin,

Abstract

AFT-50 EndoMAP: A phase IB/II multicohort study of targeted agents and/or immunotherapy for patients with recurrent or persistent endometrial cancer (EC).

Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Alliance Statistics and Data Management Center, Mayo Clinic Rochester, Rochester, MN, University of Chicago Medicine, UCSF Helen Diller Family Comprehensive Cancer Center,

Abstract

SMART: A phase II study of sacituzumab govitecan (SG) with or without atezolizumab immunotherapy in rare genitourinary (GU) tumors such as small cell, adenocarcinoma, and squamous cell bladder/urinary tract cancer, renal medullary carcinoma (RMC) and penile cancer.

Org: Genitourinary Malignancies Branch, CCR, NCI, NIH, Bethesda, MD, New York University Grossman School of Medicine, New York, NY, Urologic Oncology Branch, CCR, NCI, NIH, Bethesda, MD, Radiology and Imaging Sciences, CCR, NCI, NIH, Bethesda, MD, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD,

Abstract

An open-label, multicenter study investigating RP2 oncolytic immunotherapy in combination with second-line systemic atezolizumab combined with bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.

Org: Pusan National University and Biomedical Research Institute, Pusan National University Hospital, Replimune, Inc., Clinical Cooperation Unit Virotherapy, German Cancer Center Research Center (DKFZ),

Abstract

Safety and toxicity evaluation of the combination of selinexor with atezolizumab in patients with soft tissue sarcomas.

Org: Early Clinical Trials Development Program, Biometric Research Branch, National Cancer Institute at Frederick,

Abstract

Efficacy and safety of atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer: An interim analysis of the atezobladderpreserve phase II trial (SOGUG-2017-A-IEC(VEJ)-4).

Org: Medical Oncology Department-Complejo Hospitalario Universitario de Ourense, Hospital Universitari Parc Taulí, HU Sant Joan de Reus, Hospital Universitario San Cecilio, Medical Oncology Department, Fundació Althaia,

Abstract

FDA analysis of immune checkpoint inhibitors in combination with vascular endothelial growth factor tyrosine kinase inhibitors in the second-line treatment of patients with advanced non-small cell lung cancer.

Org: U.S. Food and Drug Administration, Silver Spring, MD, Office of Oncologic Diseases, Center for Drug Evaluation and Research, Oncology Center of Excellence,

Abstract

Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive melanoma with central nervous system (CNS) metastases (mets): Final results and exploratory biomarker analysis from the phase 2 TRICOTEL study.

Org: University of Zürich Hospital, ISS AG, Integrated Scientific Services,

Abstract

IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).

Org: Tongji University Affiliated Shanghai Pulmonary Hospital, Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rend.Int., Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary, MI Zaporizhzhia Regional Clinical Oncological Dispensary Zaporizhzhia SMU Ch of Oncology, LKI Lungenfachklinik Immenhausen,

Abstract

Cost-effectiveness in perioperative therapy in the era of immune checkpoint inhibitors.

Org: Juntendo University Graduate School of Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine,

Abstract

Phase 2/3 study of livmoniplimab in combination with budigalimab in patients with locally advanced or metastatic hepatocellular carcinoma.

Org: Weill Medical College at Cornell University, Liver Oncology and Therapeutic Innovation Unit, AP-HP-Hôpital Beaujon, Clichy, France, Department of Oncology, National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan, Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Department of Medicine, Section of Hematology and Oncology, University of Chicago,

Abstract

First-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma (RCC): An international multi-center study.

Org: Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, Dana-Farber Cancer Institute, Boston, MA, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, Rogel Comprehensive Cancer Center, Ann Arbor, MI, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, Tom Baker Cancer Centre, University of Calgary, Alberta, Canada, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic, City of Hope Comprehensive Cancer Center, Duarte, CA, Genitourinary Medical Oncology, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Campus Biomedico, Roma, Italy, University Hospital of Parma, Fontevivo, Italy, Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, United Kingdom, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, Vanderbilt University Medical Center, Nashville, TN, Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA,

Abstract

Beacon: A phase II study of bevacizumab, atezolizumab, and cobimetinib in patients with recurrent, platinum resistant, high grade serous ovarian cancer.

Org: The Royal Women’s Hospital, Cancer Immunology Research,

Abstract

SWOG S2012: Randomized phase II/III trial of first line platinum (P)/etoposide (E) with or without atezolizumab (NSC #783608) in patients with advanced or metastatic poorly differentiated extrapulmonary neuroendocrine carcinomas (NEC).

Org: Department of Thoracic/Head and Neck Medical Oncology,

Abstract

Randomized phase III study comparing suspension or continuation of PD-1 pathway blockade for patients with advanced non-small-cell lung cancer (SAVE study: JCOG1701).

Org: Department of Medical Oncology, Kyorin University Faculty of Medicine, Mitaka, Japan, JCOG Data Center/Operations Office, National Cancer Center, Tokyo, Japan, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan, Miyagi Cancer Center, Natori-Shi, Japan,

Abstract

Phase 1/2 randomized, open-label, multicenter, Simon two-stage study of pelareorep combined with modified FOLFIRINOX +/- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma.

Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, AK Altona, Asklepios Tumourzentrum Hamburg, Oncolytics Biotech, Calgary, AB, Canada,

Abstract

Effect of antibiotic, proton pump inhibitor, H2 blocker, metformin and statin use on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in a real-world setting.

Org: John D. Dingell VA Hospital,

Abstract

A randomized phase II trial of atezolizumab with or without tiragolumab before and after definitive chemoradiation for unresectable stage III non-small cell lung cancer (NSCLC; AFT-57).

Org: Rush University Cancer Center, Ideker Laboratory, Alliance Foundation Trials,

Abstract

Cabozantinib plus atezolizumab in patients with advanced and progressive neuroendocrine neoplasms (NENs): A prospective multi-cohort basket phase II trial (CABATEN / GETNE-T1914).

Org: University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario 12 de Octubre, Imas12, UCM, Hospital Universitario La Paz, IdiPAZ, Hospital Universitario Central de Asturias, ISPA, Catalan Institute of Oncology (ICO-Badalona) Germans Trias i Pujol University Hospital,

Abstract

J-TAIL-2: A prospective, observational study of atezolizumab (atezo) combined with carboplatin and etoposide (CE) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) in Japan.

Org: Department of Respiratory Medicine, Tohoku University, Sendai, Japan, Department of Respiratory Medicine and Allergy, Okayama University Hospital, Okayama, Japan, Department of Pulmonary and Breast Surgery, Oita University School of Medicine, Oita, Japan, Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan, Department of Respiratory Medicine, Kanazawa University, Kanazawa, Japan,

Abstract

INSIGHT-005: A new stratum of the explorative, open-labeled, phase I INSIGHT study to evaluate the feasibility and safety, as well as preliminary efficacy, of subcutaneous injections with IMP321 (eftilagimod alpha) in combination with PD-L1 inhibitor (avelumab) for metastatic or unresectable locally advanced urothelial carcinoma (UC)—IKF-s614.

Org: Universitätsklinik Tübingen, Klinik für Urologie, University Medical Center of the Johannes Gutenberg-University Mainz, Hematology Oncology Practice Eppendorf (HOPE), University Cancer Center Hamburg (UCCH),

Abstract

NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC).

Org: NRG Oncology Statistical and Data Management Center, Department of Biostatistics at University of Pittsburgh School of Public Health, NSABP Foundation, Inc., UPMC Hillman Cancer Center, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC,

Abstract

Atezolizumab + bevacizumab versus lenvatinib as first-line systemic therapy for treatment of hepatocellular carcinoma in a real-world population: Outcomes from the HCC CHORD database.

Org: Halifax, NS, Canada, Winnipeg, MB, Canada,

Abstract

Cobimetinib plus atezolizumab for RAS and NF1/2-mutated poorly differentiated thyroid carcinoma.

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX,

Abstract

A multicohort platform trial to improve drug access for pediatric cancer patients in Japan: The PARTNER trial (NCCH2220).

Org: Department of Pediatric Oncology,

Abstract

DAREON-8: A phase I, open-label, dose escalation/expansion trial of the DLL3-targeting T-cell engager, BI 764532, combined with first-line (1L) standard of care (platinum, etoposide, and anti-PD-L1 antibody) in patients (pts) with extensive-stage small cell lung carcinoma (ES-SCLC).

Org: Boehringer Ingelheim, France S.A.S., Boehringer Ingelheim (China) Investment Co., Ltd.,

Abstract

First-line (1L) treatment of follicular lymphoma (FL) with atezolizumab and obinutuzumab (A+O) +/- radiotherapy (RT): Results from the FLUORO study.

Org: Grampians Health, Austin Health and University of Melbourne, Olivia Newton-John Cancer Research Institute and La Trobe University, Murdoch Children's Research Institute,

Abstract

J-TAIL-2: A prospective observational study of atezolizumab (atezo) combination therapy in patients (pts) with non-small cell lung cancer (NSCLC) in Japan.

Org: Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan, Department of Thoracic Oncology, Kansai Medical University, Osaka, Japan, Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, Fukujuji Hospital, Tokyo, Japan, Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan,

Abstract

Outcome of chemo-immunotherapy for extensive-stage small-cell lung cancer according to potential clinical trial eligibility: 3-year outcomes from prospective cohort study.

Org: Kobe Minimally Invasive Cancer Center, Hyogo Prefectural Amagasaki General Medical Center, NHO Kinki-Chuo Chest Medical Center, NHO Osaka Toneyama Medical Center, Itami City Hospital,

Abstract

Effect of AURKA targeting on nuclear PD-L1 and the efficacy of immune checkpoint inhibitors in triple-negative breast cancer.

Org: Mayo Clinic, Rochester, MN,

Abstract

Possibilities of long-term atezolizumab immunotherapy in patients with metastatic urothelial cancer.

Org: Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, Tashkent, Uzbekistan,

Clinical trial

A Phase 2, Randomized, Open-label Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer in Patients With a KRAS or NRAS Mutation

Status: Recruiting, Estimated PCD: 2026-11-01

Clinical trial

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV07/ ENGOT-ov80 Study)

Status: Not yet recruiting, Estimated PCD: 2027-08-31

Clinical trial

A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy

Status: Active (not recruiting), Estimated PCD: 2022-12-31

Abstract

N2M2/NOA-20: Phase I/IIa umbrella trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation.

Org: University of Heidelberg, NCT Heidelberg, Heidelberg University Hospital, Department of Neurology and Hematology-Oncology, Department of Neuroradiology,

Abstract

JCOG2002: A randomized phase III study of thoracic radiotherapy for extensive stage small cell lung cancer.

Org: Department of Radiation Oncology, Iizuka Hospital, Iizuka, Japan, Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, Mibu, Japan, Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan, Department of Clinical Oncology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan, Yokohama Municipal Citizen's Hospital, Yokohama, Japan,

Abstract

Hepatic artery infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced hepatocellular carcinoma with portal vein tumor thrombus: A single center retrospective study.

Org: Department II of Interventional Radiology,

Abstract

BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial.

Org: Royal Marsden Hospital NHS Foundation Trust, Medical Oncology Service, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), National and Kapodistrian University of Athens,

Abstract

A real-world study of anlotinib in combination with PD-L1 inhibitors plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer.

Org: First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou Anjie Biomedical Technology Co. Ltd,

Abstract

STELLAR-303: A randomized phase 3 study of zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated metastatic colorectal cancer.

Org: Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC,

Abstract

With eyes on the future: Prospective evaluation of immune-related adverse events in patients with lung cancer.

Org: Hospital das Clinicas UFMG,

Abstract

Preliminary results of atezolizumab and pirfenidone in non-small cell lung cancer.

Org: University of Kansas Medical Center, Department of Biostatistics & Data Science,

Abstract

Atezolizumab plus taxane chemotherapy for the treatment of non-BRAF, non-RAS mutated anaplastic thyroid carcinoma: Final analysis.

Abstract

Preliminary safety data of the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial assessing the triple combination atezolizumab-bevacizumab-ipilimumab in patients (pts) treated in systemic therapy for hepatocellular carcinoma (HCC).

Org: Croix-Rousse Hospital, Service d’Hépato-Gastroentérologie, Hôpital Purpan, FFCD - INSERM U1231, Hopital Duchenne,

Abstract

Combination or sequence of vemurafenib, cobimetinib, and atezolizumab in high-risk, resectable melanoma (NEO-TIM): Primary results.

Org: Deparment of Medical Oncology, IRCCS Ospedale Policlinico San Martino, Immunotherapy and Cell Therapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, IRCCS Istituto Oncologico di Bari Giovanni Paolo II, Oncology Department, Institute of Dermatology, Catholic University Fondazione Policlinico Universitario, Medical Oncology Unit, Department of Oncology, Santa Maria Annunziata Hospital, Azienda USL Toscana Centro,

Abstract

A single institution review of immunotherapy use, adverse events, and outcomes in early-onset cancer.

Org: University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, University Hospitals Center for Clinical Research, Case Western Reserve University School of Medicine, University Hospitals Sussex NHS Foundation Trust,

Abstract

Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis.

Org: Bio-Medico Campus University Hospital,

Abstract

Overlapping and non-overlapping indications for checkpoint inhibitors in the US.

Org: Brigham and Women's Hospital, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Memorial Sloan Kettering Cancer Center,

Abstract

Association of ephrinB2 (B2) expression on overall survival (OS) and resistance to PD1/L1 inhibitors (inh) in metastatic urothelial carcinoma (mUC).

Org: Vasgene Therapeutics, Inc, Newark, NJ, Orlando, FL,

Abstract

Molecular analysis of the HCRN GU16-260-Cohort A phase II study of first-line (1L) nivolumab (nivo) and salvage nivo + ipilimumab (ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC).

Org: Hackensack, NJ, University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center,

Abstract

FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.

Org: Department of Peptide-based Immunotherapy, Institute of Immunology,

Abstract

Tislelizumab plus tyrosine kinase inhibitor versus active surveillance in patients with ablated high-risk hepatocellular carcinoma: An open-label, parallel controlled, prospective cohort study.

Org: Hefei, China,

Abstract

Prognostication of ß-catenin (CTNNB1) in patients with HCC treated with first line immunotherapy.

Org: Mayo Clinic, Mayo Clinic Cancer Center, Alliance Statistics and Data Management Center,

Abstract

Cost analysis of targeted and immunotherapies in operable esophageal and non-small cell lung cancers.

Org: Division of General Thoracic Surgery, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery,

Abstract

CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study.

Org: Department of Surgery, National Cheng Kung University Hospital, Tainan, Taiwan, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, Division of Hepato-Gastroenterology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan,

Abstract

SB221: A proof-of-concept study to assess the combination of SON-1010 (IL12-FHAB) and atezolizumab in patients with platinum-resistant ovarian cancer.

Org: Blacktown Cancer and Hematology Centre, Albury Wodonga Cancer Care,

Abstract

Enhancing the efficacy of anti-PD-L1 therapy by cabozantinib in the treatment of advanced esophageal squamous cell carcinoma (ESCC): Rationales from a preclinical study.

Org: National Taiwan University Cancer Center/Hospital, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, National Taiwan University Hospital Yunlin Branch,

Abstract

Use of immunotherapy with check point inhibitors in soft tissue sarcoma: Analysis from single institution.

Org: University of Louisville, James Graham Brown Cancer Center,

Abstract

Stereotactic body radiation therapy combined with atezolizumab and bevacizumab for hepatocellular carcinoma with extrahepatic metastasis: Preliminary result of a single-arm study.

Org: Fudan University Shanghai Cancer Center, Shanghai Henlius Biotech, China National Biotec Group,

Abstract

Systematic literature review and network meta-analysis of first-line therapies for locally advanced/metastatic urothelial carcinoma.

Org: Curta Inc.,

Abstract

Survival differences in advanced non-small cell lung cancer after developments in regimens with immune check point inhibitors: Population based retrospective study from United States SEER database.

Org: Montgomery Regional Medical Campus,

Abstract

First-line (1L) systemic therapy in locally advanced/metastatic urothelial cancer (Ia/mUC): A living interactive systematic review and network meta-analysis.

Org: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Division of Hematology and Medical Oncology, Mayo Clinic, Phoeniz, AZ,

Abstract

Tislelizumab plus sitravatinib as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after surgical resection: Preliminary analysis of a multi-center, non-randomized, open-label phase 2 study.

Org: The First Affiliated Hospital of USTC, Hefei, China, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, The First Affiliated Hospital of Xi'an Jiaotong University, Xi 'an, China, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China,

Abstract

Efficacy and safety of PARP inhibitors (PARPi) with immune checkpoint inhibitors (ICI) in metastatic castration-resistant prostate cancer (mCRPC): A systematic review and single-arm meta-analysis.

Org: Hospital do Servidor Público do Estado de São Paulo, Faculdade de Medicina de Barbacena FAME - FUNJOB, Centro de Oncologia do Paraná,

Abstract

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer.

Org: Emory University School of Medicine and Winship Cancer Institute, Investigational Drug Branch, Winship Cancer Institute of Emory Univeristy,

Abstract

Efficacy and safety of regorafenib combined with PD-1 inhibitors in patients with advanced hepatocellular beyond atezolizumab plus bevacizumab: A retrospective analysis of real-world evidence.

Org: The PLA 307 Clinical College of Anhui Medical University, The Fifth Clinical Medical College of Anhui Medical University, Institute of Molecular Medicine (IMM),

Abstract

The pan-cancer landscape of SMARCA4 and SMARCB1 alterations in a large cohort of Chinese patients.

Org: General Hospital of Central Theater Command, Suzhou, China,

Abstract

The safety of atezolizumab plus bevacizumab (atezo/bev) treatment in Chinese patients (pts) with hepatocellular carcinoma (HCC) with active hepatitis B virus (HBV) infection: Results from the TALENTop study.

Org: Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, Department of Hepatobiliary Pancreatic Surgery, Henan Provincial People's Hospital, Zhengzhou, China, Department of Liver Surgery & Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, China,

Clinical trial

Phase II Study of Stereotactic Body Radiation Therapy and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

Status: Recruiting, Estimated PCD: 2025-10-01

Abstract

Response rate with cetuximab used less than 3 months after immunotherapy (IO) for recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) compared to larger delay.

Org: Owkin France, Centre Leon Berad,

Abstract

The efficacy of atezolizumab plus bevacizumab in the treatment of unresectable hepatocellular carcinoma in cirrhotic and non-cirrhotic patients.

Org: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico,

Abstract

The treatment outcomes of patients who failed to be randomly assigned after atezo/bev induction therapy in the Chinese TALENTop study.

Org: Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Department Of Hepatic Surgery, Shanghai Eastern Hepatobiliary Surgery Hospital, SYSUCC, Guangzhou, Tongji Hospital, Huazhong University of Science and Technology, Liver Cancer Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin’s Clinical Research Center for Cancer,

Abstract

Des-gamma-carboxy prothrombin (DCP) as a prognostic biomarker in patients with advanced hepatocellular carcinoma treated with atezolizumab/bevacizumab.

Org: University of California, San Diego, San Diego, CA, UC San Diego Moores Cancer Center, San Diego, CA,

Abstract

A retrospective study of first line atezolizumab-carboplatin-etoposide in extensive-stage small cell lung cancer: Real world data from a Spanish tertiary center.

Org: Department of Medical Oncology, Cruces University Hospital, Barakaldo, Spain, Department of Medical Oncology. Hospital universitario de Cruces, Barakaldo, Spain, Department of Medical Oncology. Hospital Universitario Cruces, Barakaldo, Spain, Deparment of Medical Oncology. Cruces University Hospital, Barakaldo, Spain, Department of Medical Oncology of Cruces University Hospital, Barakaldo, Spain,

Clinical trial

Niraparib vs Niraparib in Combination With Bevacizumab in Patients With Carboplatinum-taxane Based Chemotherapy in Advanced Ovarian Cancer (A Multicentre Randomised Phase III Trial)

Status: Recruiting, Estimated PCD: 2028-02-01

Clinical trial

Effectiveness & Safety of Perfenidone in Type 2 Diabetic Patients With Diabetic Neuropathy: A Randomized Controlled Trial

Status: Recruiting, Estimated PCD: 2025-03-09

Clinical trial

Investigation of Antitumor Immune Response in Patients With Unresectable Hepatocellular Carcinoma Undergoing Photon Radiotherapy Combined With Atezolizumab and Bevacizumab

Status: Not yet recruiting, Estimated PCD: 2029-03-30

Abstract

Interchangeability of anti-PD1 antibodies in patients (pts) with metastatic NSCLC.

Org: Moskovskii Mnogoprofilnyi Klinicheskii Tcentr Kommunarka Departamenta Zdravoohraneniia Goroda Moskvy, N.N. Blokhin National Medical Cancer Research Center of the Ministry of Healthcare of the Russian Federation, Federal State Budgetary Institution N.N. Blokhin National Medical Research Center of Oncology, Clinical and Scientific Research Practical Oncological Center, Saint Petersburg Scientific Practical Center of Specialized Kinds of Medical Care,

Clinical trial

A Multicenter, Single-arm Study of Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer

Status: Not yet recruiting, Estimated PCD: 2025-11-30

Abstract

Cardiomyopathy among recipients of immune checkpoint inhibitor therapy: A prospective study.

Org: Division of Cardiovascular Imaging, St. Francis Hospital & Heart Center, DeMatteis Cardiovascular Institute of St. Francis Hospital, Cardio-Oncology Service, Cardiology Division,

Abstract

Anlotinib combined with penpulimab as first-line treatment for persistent, recurrent, or metastatic cervical cancer: Preliminary results from ALTER-GO-020, a single-arm, open-label, multi-cohort, multi-center phase II clinical study.

Org: Shanxi Provincial People’s Hospital, Xi'an, China, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Sichuan Cancer Hospital & Institute, Sichuan, Cancer Center, Chengdu, China,

Abstract

The outcomes of atezolizumab therapy in combination with carboplatin and etoposide for small-cell lung cancer.

Org: Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, Tashkent, Uzbekistan,

Abstract

Real-world data (RWD) with avelumab in patients (pts) with locally advanced or metastatic urothelial cancer (la-mUC): The AVEBLADDER study.

Org: Universidad Europea del Atlántico, Hospital Universitario de Navarra, Valladolid University Clinical Hospital, Hospital Universitario de Araba-Txagorritxu, Hospital Universitario Galdakao-Usansolo,

Abstract

Monocyte/lymphocyte ratio to predict immunoradiotherapy response in patients with advanced pretreated sarcoma.

Org: Gustave Roussy Cancer Campus, Gustave Roussy Département d'Organisation du Parcours Patient, University of Navarra Clinic, Pamplona, Spain, F. Hoffmann-La Roche Ltd,

Abstract

Efficacy and safety of second-line immunotherapy in patients with advanced non-small cell lung cancer.

Org: Hospital Juan Ramón Jiménez, Hospital Juan Ramon Jimenez, Aodo Asociación Onubense Para,

Abstract

Effect of combinatorial immune checkpoint blockade on myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β, and interleukin-6: Biochemical implications in cardio-immuno-oncology.

Org: Division of Cardiology, Istituto Nazionale Tumori –IRCCS- Fondazione G. Pascale, Naples, Italy, IRCCS Fondazione G. Pascale, Napoli, Italy, Department of Molecular Medicine and Medical Biotechnology, University of Naples “Federico II”, Naples, Italy, Servizi Cardiologici Integrati, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy, Oncologia Medica, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar Di Valpolicella, Italy,

Clinical trial

Phase I Trial of Bevacizumab, Metronomic Doxorubicin and Radiation Therapy for Resectable Soft Tissue Sarcoma

Status: Active (not recruiting), Estimated PCD: 2016-05-01

Clinical trial

A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

Status: Active (not recruiting), Estimated PCD: 2022-04-12

Clinical trial

Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation

Status: Withdrawn, Estimated PCD: 2006-12-01

Clinical trial

Phase II Study of Maintenance Anti-PD-L1 Treatment With Atezolizumab After Chemo-radiotherapy for Muscle-infiltrating Bladder Cancer Patients Not Eligible for Radical Cystectomy: Bladder Sparing

Status: Active (not recruiting), Estimated PCD: 2025-06-15

Clinical trial

ANGIO-A: Safety and Tolerability of Oral Cyclophosphamide and Sorafenib With Intravenous Bevacizumab With the Addition of Atezolizumab in Pediatric Solid Tumor Patients

Status: Recruiting, Estimated PCD: 2032-06-01

Clinical trial

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Status: Recruiting, Estimated PCD: 2026-09-01

Clinical trial

Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer:a Multicenter, Phase I/II Trial.

Status: Not yet recruiting, Estimated PCD: 2025-06-05

Clinical trial

An Open-Label Pilot Study to Evaluate Efficacy and Safety of Bevacizumab Via Transarterial Chemoembolization (TACE) in Patients With Liver Metastases

Status: Not yet recruiting, Estimated PCD: 2024-06-01

Clinical trial

Prospective Safety Study of Sintilimab Combined With XELOX Plus Bevacizumab for Preoperative Neoadjuvant Therapy of CRLM Patients With pMMR/MSS Status

Status: Active (not recruiting), Estimated PCD: 2023-10-30

Clinical trial

A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)

Status: Recruiting, Estimated PCD: 2027-07-01

Clinical trial

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

Status: Recruiting, Estimated PCD: 2028-05-01

Clinical trial

A Phase II Randomized Study of Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

Status: Terminated, Estimated PCD: 2023-11-27

Clinical trial

A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination With Atezolizumab Compared to Atezolizumab Alone in Subjects With Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option

Status: Active (not recruiting), Estimated PCD: 2025-06-30

Clinical trial

A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status: Terminated, Estimated PCD: 2022-09-27

Clinical trial

Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer. A Randomized Phase II Marker Trial

Status: Recruiting, Estimated PCD: 2024-10-01

Clinical trial

Randomized, Phase II Trial to Evaluate the Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy Compared to Capecitabine Monotherapy for TNBC With Residual Invasive Cancer After Neoadjuvant Chemotherapy.

Status: Active (not recruiting), Estimated PCD: 2024-01-31

Clinical trial

Women's Triple-Negative First-Line Study: A Phase II Trial of Liposomal Doxorubicin, Bevacizumab and Everolimus (DAE) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy

Status: Completed, Estimated PCD: 2023-05-24

Clinical trial

A Randomized Phase 2 Study of Atezolizumab in Combination With Cobimetinib Versus Atezolizumab Monotherapy in Participants With Unresectable Cholangiocarcinoma

Status: Completed, Estimated PCD: 2020-08-07

Clinical trial

A Phase 2 Study of Bevacizumab for Chronic Bleeding and Iron Deficiency Anemia in Hereditary Hemorrhagic Telangiectasia

Status: Recruiting, Estimated PCD: 2026-04-01

Clinical trial

A Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

Status: Completed, Estimated PCD: 2022-12-29

Clinical trial

A Randomized Phase II Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Status: Terminated, Estimated PCD: 2023-06-18

Clinical trial

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Status: Active (not recruiting), Estimated PCD: 2024-12-01

Clinical trial

ML42362: Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma

Status: Active (not recruiting), Estimated PCD: 2024-02-15

Clinical trial

Umbrella Protocol for Phase I/IIa Trials of Molecularly Matched Targeted Therapies Plus Radiotherapy in Patients With Newly Diagnosed Glioblastoma Without MGMT Promoter Methylation: NCT Neuro Master Match - N²M² (NOA-20)

Status: Completed, Estimated PCD: 2023-02-22

Clinical trial

Phase II Open Label, Single-Arm Study of Cabozantinib in Combination With Atezolizumab in the Treatment of Locally Advanced or Metastatic Adrenocortical Carcinoma

Status: Active (not recruiting), Estimated PCD: 2025-12-16

Clinical trial

A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

A Prospective, Multicenter, Open, Randomized Controlled Phase II Clinical Study Evaluating Recombinant Oncolytic HSV2（OH2）Therapeutic Injecta(Vero Cell) for Human Use(rHSV2hGM-CSF) in Combination With Capecitabine for First-line Maintenance Therapy in Advanced Colorectal Cancer

Status: Terminated, Estimated PCD: 2024-04-15

Clinical trial

Phase I/II Trial of Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed Glioblastoma Multiforme

Status: Completed, Estimated PCD: 2021-08-01

Clinical trial

A Phase II Clinical Trial Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) in Patients Previously Treated With PD-1-directed Therapy

Status: Completed, Estimated PCD: 2021-12-31

Clinical trial

A Phase II Trial of Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium

Status: Completed, Estimated PCD: 2020-05-12

Clinical trial

An Open-Label Phase 1b Dose-Finding Trial Evaluating the Safety of Niraparib and Temozolomide and Atezolizumab in Participants With Advanced Solid Tumors and Expansion to a Phase 2 Trial Comparing the Effects of Niraparib and Temozolomide Plus Atezolizumab vs. Atezolizumab as Maintenance Therapy in Participants With Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy (TRIO-US L-06)

Status: Recruiting, Estimated PCD: 2025-01-03

Clinical trial

A Phase Ib/II Study to Evaluate Safety and Efficacy of Atezolizumab Combined With Radio-chemotherapy in a Preoperative Setting for Patients With Localized Rectal Cancer

Status: Active (not recruiting), Estimated PCD: 2024-02-22

Clinical trial

Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IV Mycosis Fungoides/Sezary Syndrome Patients Relapsed/Refractory After a Previous Systemic Treatment

Status: Terminated, Estimated PCD: 2021-03-11

Clinical trial

A Phase I Study of Riluzole in Combination With mFOLFOX6/Bevacizumab in Patients With Metastatic Colorectal Cancer

Status: Active (not recruiting), Estimated PCD: 2023-05-06

Clinical trial

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer

Status: Active (not recruiting), Estimated PCD: 2023-05-09

Clinical trial

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

Status: Recruiting, Estimated PCD: 2024-07-31

Clinical trial

Phase 1 Clinical Trial of ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Status: Recruiting, Estimated PCD: 2025-01-15

Clinical trial

Overcoming Resistance to Immunotherapy Combining Gemcitabine With Atezolizumab in Advanced NSCLC and Mesothelioma Progressing Under Immune-checkpoint Inhibitors or Gemcitabine. A Multicenter, Single-arm, Open Label Phase II Trial With Two Cohorts

Status: Active (not recruiting), Estimated PCD: 2024-05-01

Clinical trial

An Open-label, Single-Center, Phase 1b/2 Study to Evaluate the Safety of Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Malignancies After Progression on PD-1 or PD-L1 Targeted Antibodies

Status: Recruiting, Estimated PCD: 2025-06-01

Clinical trial

A Phase II Study of Atezolizumab in Combination With Stereotactic Radiation for Patients With Triple-negative Breast Cancer and Brain Metastasis

Status: Active (not recruiting), Estimated PCD: 2019-11-21

Clinical trial

A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer

Status: Active (not recruiting), Estimated PCD: 2024-07-17

Clinical trial

A Phase Ib Dose De-Escalation Study of All-Trans Retinoic Acid (ATRA) and Atezolizumab in Patients With Advanced Non-Small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

(TESSERACT): Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation (TBI)

Status: Recruiting, Estimated PCD: 2027-06-30

Clinical trial

A Randomized, Multi-Cohort Phase II Trial of Temozolomide and Atezolizumab as Second or Third Line Treatment for Small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

A Phase II Study of Atezolizumab and Bevacizumab in Child-Pugh B7 and B8 Hepatocellular Carcinoma (The AB7 Trial)

Status: Active (not recruiting), Estimated PCD: 2024-10-01

Clinical trial

A Phase 1 Study of Entinostat in Combination With Atezolizumab / Carboplatin / Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer

Status: Completed, Estimated PCD: 2021-12-30

Clinical trial

REVERT- Liver Cancer: A Phase 1b/2 Multicenter, Open-label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Status: Recruiting, Estimated PCD: 2025-03-01

Clinical trial

MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer

Status: Active (not recruiting), Estimated PCD: 2027-03-17

Clinical trial

TRIFLUOX-DP: Safety of Trifluridine/Tipiracil as Replacement of Fluoropyrimidines (5-fluorouracil and Capecitabine) Based Chemotherapy as First Line Metastatic Colorectal or Gastroesophageal Cancer Regimens in Patients With Dihydropyrimidine Dehydrogenase Deficiency: a Phase II Trial

Status: Not yet recruiting, Estimated PCD: 2026-06-22

Clinical trial

A Single Arm Phase II Trial Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Early Relapsing Metastatic Triple Negative Breast Cancer

Status: Recruiting, Estimated PCD: 2025-09-01

Clinical trial

CAFs (Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC): a Phase I/II Study

Status: Recruiting, Estimated PCD: 2024-08-01

Clinical trial

DETERRED: PD-L1 blockadE To Evaluate the Safety of Lung CanceR Therapy Using Carboplatin, Paclitaxel, and Radiation CombinEd With MPDL3280A

Status: Active (not recruiting), Estimated PCD: 2026-01-31

Clinical trial

Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases: A Single-center, Prospective, Randomized Controlled Phase II Study

Status: Recruiting, Estimated PCD: 2026-01-30

Clinical trial

Efficacy and Safety of Modified Hepatic Artery Infusion Chemotherapy (TOMOX-HAIC) in Combination With Sintilimab and Bevacizumab Biosimilar for the First-line Treatment of Advanced Hepatocellular Carcinoma: a Prospective, Single-arm, Phase II Clinical Study

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

Status: Active (not recruiting), Estimated PCD: 2025-01-01

Clinical trial

Neo-Adjuvant Study With the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment With Nab-paclitaxel and Carboplatin

Status: Completed, Estimated PCD: 2024-01-01

Clinical trial

Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC: A Retrospective Cohort Study Based on Propensity Score Matching

Status: Completed, Estimated PCD: 2022-10-31

Clinical trial

Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients With Recurrent Medulloblastoma and Ependymoma

Status: Active (not recruiting), Estimated PCD: 2029-10-30

Clinical trial

A Phase II Study of 5-FU, Irinotecan, Bevacizumab and Hydroxychloroquine in Drug-Tolerant Persister (DTP)-Selected Patients With Metastatic Colorectal Cancer

Status: Recruiting, Estimated PCD: 2026-04-24

Clinical trial

Prospective, Randomized, Open, Multicenter Phase II Trial to Investigate the Efficacy of Trifluridine/Tipiracil Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer: FIRE-8; AIO-KRK/YMO-0519

Status: Recruiting, Estimated PCD: 2029-12-01

Clinical trial

Randomised Study to Investigate FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab as First-line Treatment of BRAF-mutated Metastatic Colorectal Cancer

Status: Active (not recruiting), Estimated PCD: 2023-11-01

Clinical trial

Phase III Randomized Trial of Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Monthly Carboplatin With Weekly Paclitaxel Chemotherapy

Status: Active (not recruiting), Estimated PCD: 2024-12-01

Clinical trial

A Phase II, Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung

Status: Recruiting, Estimated PCD: 2028-01-31

Clinical trial

A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Status: Recruiting, Estimated PCD: 2025-09-30

Clinical trial

A Phase II, Open-Label, Single-Arm, Multi-Cohort, Proof-of-Principle Study to Investigate the Efficacy of Cobimetinib and Atezolizumab in Advanced Rare Tumors

Status: Completed, Estimated PCD: 2024-04-02

Clinical trial

Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, With or Without Atezolizumab in Triple Negative Breast Cancer (TNBC)

Status: Active (not recruiting), Estimated PCD: 2019-12-18

Clinical trial

Effectiveness of Atezolizumab in Large Cell Neuroendocrine Carcinoma of the Lung and the Value of miR21 and miR-375 as Biomarkers

Status: Completed, Estimated PCD: 2022-08-01

Clinical trial

Atezolizumab in Combination With Gemcitabine and Cisplatin As First-Line Treatment in Metastatic Urothelial Cancer: A Multicenter Randomized Phase II Study of Two Alternative Dosing Schedules

Status: Active (not recruiting), Estimated PCD: 2025-03-01

Clinical trial

Phase II Single-arm, Single-center Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Refractory Microsatellite Stable Colorectal Cancer

Status: Recruiting, Estimated PCD: 2026-10-01

Clinical trial

Phase 1 Clinical Trial of Personalized Neoantigen Tumor Vaccines and Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Surgically Resected Pancreatic Cancer

Status: Active (not recruiting), Estimated PCD: 2024-11-11

Clinical trial

A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab in Subjects With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment

Status: Recruiting, Estimated PCD: 2030-09-06

Clinical trial

Phase 1 Trial of Umbilical Cord Blood Natural Killer Cells (CB-NK) Expressing Soluble IL-15 (sIL-15) and PD-L1 +/- Atezolizumab in Non-Small Cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors

Status: Active (not recruiting), Estimated PCD: 2025-09-30

Clinical trial

MEGALiT - a Multicenter, Basket and Umbrella Explorative Trial on the Efficacy and Safety of Molecular Profile Selected Commercially Available Targeted Anti-cancer Drugs in Patients With Advanced Cancers Progressive on Standard Therapy

Status: Recruiting, Estimated PCD: 2024-01-31

Clinical trial

A Single-arm Phase 2 Study of Atezolizumab as Induction Therapy in Stage IB-IIIA Non N2 Resectable and Untreated Non-small Cell Lung Cancer (NSCLC)

Status: Completed, Estimated PCD: 2023-03-01

Clinical trial

Non-Randomized, Open-Label, Prospective Phase II Trial to Better Characterize the Status of HRD Leading to a Benefit From Olaparib in Combination With Bevacizumab in Patients With Advanced FIGO Stage III-IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer After Standard First-Line Treatment

Status: Recruiting, Estimated PCD: 2024-03-01

Clinical trial

A Multi-institutional Phase II Study to Evaluate Efficacy and Safety of TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer

Status: Terminated, Estimated PCD: 2022-02-18

Clinical trial

Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity - DARWINII

Status: Active (not recruiting), Estimated PCD: 2026-05-01

Clinical trial

A Single Arm Phase 2 Trial of Atezolizumab With Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer (ASPRIA)

Status: Active (not recruiting), Estimated PCD: 2025-12-30

Clinical trial

The ABC-HCC Trial: A Phase IIIb, Randomized, Multicenter, Open-label Trial of Atezolizumab Plus Bevacizumab Versus Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

Status: Recruiting, Estimated PCD: 2025-04-01

Clinical trial

Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (Anti-PD-L1) in Combination With Cabozantinib in Patients With Recurrent Glioblastoma (rGBM)

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer

Status: Active (not recruiting), Estimated PCD: 2023-03-06

Clinical trial

Short-Term Fasting Prior to Standard Checkpoint Blockade Using PD-1/PD-L1 Inhibition: A Pilot Safety and Feasibility Study

Status: Recruiting, Estimated PCD: 2024-08-12

Clinical trial

A Multicenter, Randomized, Open-label Study Evaluating the Efficacy and Safety of Hepatic Resection for Hepatocellular Carcinoma With Venous Thrombosis After Initial Atezolizumab Plus Bevacizumab Treatment

Status: Recruiting, Estimated PCD: 2027-08-31

Clinical trial

Single Arm Phase 2 Trial of Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib (TOP 1901)

Status: Terminated, Estimated PCD: 2022-11-13

Clinical trial

A Pilot Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma

Status: Withdrawn, Estimated PCD: 2023-11-10

Clinical trial

Phase II Clinical Trial Combining the Hedgehog Inhibitor Vismodegib With the PD-L1 Inhibitor Atezolizumab in Patients With Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Status: Recruiting, Estimated PCD: 2028-04-01

Clinical trial

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High TMB or MSI-high or Proven CMMRD Disposition.

Status: Recruiting, Estimated PCD: 2029-10-01

Clinical trial

A Phase 2 Trial of Atezolizumab and Cabozantinib in Adolescents and Young Adults With Recurrent/Metastatic Osteosarcoma (TACOS)

Status: , Estimated PCD: 2027-12-31

Clinical trial

An Open-Label Multi-Center Phase II Study of Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

Status: Recruiting, Estimated PCD: 2025-02-28

Clinical trial

Neoadjuvant Combination of Serplulimab and Bevacizumab With FOLFOX Versus FOLFOX Alone for Resectable Liver Metastases in RAS/BRAF Wild-Type, pMMR/MSS Colorectal Cancer Patients

Status: Recruiting, Estimated PCD: 2026-12-31

Clinical trial

Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia and Richter Transformation

Status: Recruiting, Estimated PCD: 2025-02-28

Clinical trial

A Single-arm, Exploratory Clinical Study of SHR-A1811 Combined With Bevacizumab in the Treatment of HER2-positive Breast Cancer With Brain Metastases

Status: Not yet recruiting, Estimated PCD: 2025-05-01

Clinical trial

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Status: Recruiting, Estimated PCD: 2024-12-06

Clinical trial

Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)

Status: Active (not recruiting), Estimated PCD: 2024-06-30

Clinical trial

A Phase I/II b (Randomized Controlled) Study of Atezolizumab Combined to BEGEV Regimen as First Salvage Treatment in Patients With Relapsed or Refractory Hodgkin's Lymphoma Candidate to Autologous Stem-Cell Transplantation

Status: Recruiting, Estimated PCD: 2025-05-08

Clinical trial

Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases

Status: Terminated, Estimated PCD: 2022-07-15

Clinical trial

Phase III Double-blind Randomized Placebo Controlled Trial of Atezolizumab in Combination With Paclitaxel and Carboplatin in Women With Advanced/Recurrent Endometrial Cancer

Status: Active (not recruiting), Estimated PCD: 2025-01-01

Clinical trial

Phase II, Open-label Study of Atezolizumab in a Cohort of Pretreated, Advanced Non-small Cell Lung Cancer (NSCLC) Patients With Rare Histological Subtypes (CHANCE Trial).

Status: Completed, Estimated PCD: 2024-02-12

Clinical trial

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to Determine the Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile

Status: Recruiting, Estimated PCD: 2026-11-25

Clinical trial

Targeting Myeloid Derived Suppressor Cells in Recurrent Glioblastoma: Phase 0/1 Trial of Low Dose Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma

Status: Active (not recruiting), Estimated PCD: 2019-03-25

Clinical trial

A Single Arm, Open-label, Phase II Signal-seeking Trial of Tiragolumab and Atezolizumab in Patients With Advanced Solid Tumours.

Status: Recruiting, Estimated PCD: 2026-05-01

Clinical trial

Perioperative/Adjuvant Atezolizumab in Patients With MSI-high or MMR-deficient Stage III Colorectal Cancer Ineligible for Oxaliplatin-based Chemotherapy - a Phase II Study

Status: Recruiting, Estimated PCD: 2026-11-15

Clinical trial

A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer

Status: Recruiting, Estimated PCD: 2025-10-01

Clinical trial

Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease: a Randomized, Open-label, Multicenter Phase II Study

Status: Active (not recruiting), Estimated PCD: 2024-08-01

Clinical trial

Evaluating Novel Therapies and ctDNA as a Marker in Curatively-Treated Gastrointestinal Cancers With Microscopic Residual Disease

Status: Recruiting, Estimated PCD: 2026-12-01

Clinical trial

Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable Hepatocellular Carcinoma

Status: Recruiting, Estimated PCD: 2024-11-15

Clinical trial

An Open, Multicenter, Exploratory Clinical Study of Fluzoparib in Combination With Bevacizumab for Maintenance Therapy After First-line Platinum-containing Chemotherapy in BRCA Wild-type Advanced Ovarian Cancer

Status: Not yet recruiting, Estimated PCD: 2025-01-31

Clinical trial

The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study

Status: Recruiting, Estimated PCD: 2025-10-30

Clinical trial

A Phase 2 Study of CAbozantinib in Combination With AtezolizumaB as NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer

Status: Recruiting, Estimated PCD: 2024-05-01

Clinical trial

A Phase 2 Study of Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Status: Completed, Estimated PCD: 2018-01-01

Clinical trial

A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab Following Cytoreduction in Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer

Status: Active (not recruiting), Estimated PCD: 2024-09-27

Clinical trial

Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanced Cervical Cancer

Status: Active (not recruiting), Estimated PCD: 2024-02-26

Clinical trial

Pilot Trial of Spectroscopic MRI-guided, Dose-Escalated Proton Radiation Therapy and Bevacizumab for Recurrent Glioblastoma

Status: Recruiting, Estimated PCD: 2027-09-30

Clinical trial

Pilot Trial of Dose-Volume Constraints for Reirradiation of Recurrent Brain Tumors

Status: Active (not recruiting), Estimated PCD: 2025-07-01

Clinical trial

Single Arm, Phase IIA Clinical Trial Assessing The Safety And Efficacy of Atezolizumab in Combination With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2024-06-01

Clinical trial

A Phase Ib Open-Label Study of LB-100 in Combination With Carboplatin/Etoposide/Atezolizumab in Untreated Extensive-Stage Small Cell Lung Carcinoma

Status: Recruiting, Estimated PCD: 2026-03-09

Clinical trial

A Phase IV Trial to Confirm the Efficacy of Olaparib in Combination With Bevacizumab as Frontline Treatment of HRD Positive Ovarian Tumors

Status: Recruiting, Estimated PCD: 2027-03-15

Clinical trial

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment (ACT)

Status: Withdrawn, Estimated PCD: 2026-05-31

Clinical trial

A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

Status: Recruiting, Estimated PCD: 2024-09-01

Clinical trial

An Exploratory Clinical Trial of SHR-8068 Combined With Aldebelizumab and BP102 in the Treatment of Refractory Colorectal Cancer

Status: Not yet recruiting, Estimated PCD: 2026-11-01

Clinical trial

A Phase II Study Evaluating the Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk Diffuse Large B-cell Lymphoma

Status: Active (not recruiting), Estimated PCD: 2024-01-18

Clinical trial

A Prospective, Multicenter, Open-label, Phase II Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer

Status: Recruiting, Estimated PCD: 2024-10-31

Clinical trial

A Phase I/II Trial of the PD-L1 Inhibitor, Durvalumab Plus CV301 in Combination With Maintenance Chemotherapy for Patients With Metastatic Colorectal or Pancreatic Adenocarcinoma

Status: Terminated, Estimated PCD: 2021-08-30

Clinical trial

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers

Status: Recruiting, Estimated PCD: 2029-10-01

Clinical trial

Niraparib Maintenance Treatment in Metastatic Colorectal Cancer Patients With a Partial or Complete Response After Oxaliplatin-based Induction Therapy: Bohème Trial

Status: Withdrawn, Estimated PCD: 2023-09-04

Clinical trial

Neoadjuvant Therapy for Patients With High Risk Stage III Melanoma: A Pilot Clinical Trial

Status: Recruiting, Estimated PCD: 2025-06-29

Clinical trial

Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: a Proof of Concept Randomized Phase II Study (TERTIO - Prodige 82)

Status: Recruiting, Estimated PCD: 2025-04-30

Clinical trial

A Phase I/II Trial of Pazopanib Alternating With Bevacizumab in Treatment-Naive Metastatic Clear Cell Renal Cell Carcinoma Patients

Status: Active (not recruiting), Estimated PCD: 2025-01-02

Clinical trial

A Phase II Trial of Lamivudine in Combination With Chemoimmunotherapy in Patients With Extensive Stage SCLC

Status: Recruiting, Estimated PCD: 2025-07-01

Clinical trial

Intravesical Recombinant BCG (Bacillus Calmette Guérin) Followed by Perioperative Chemo-immunotherapy for Patients With Muscle-invasive Bladder Cancer (MIBC). A Multicenter, Single-arm Phase II Trial

Status: Recruiting, Estimated PCD: 2026-06-01

Clinical trial

Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy

Status: Recruiting, Estimated PCD: 2024-10-31

Clinical trial

A Phase II Trial of Tislelizumab as Consolidation Therapy in Patients With Locally Advanced Non-Small Cell Lung Cancer Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

Status: Recruiting, Estimated PCD: 2024-12-30

Clinical trial

Botensilimab and Balstilimab Optimization in Colorectal Cancer (BBOpCo)

Status: Not yet recruiting, Estimated PCD: 2028-07-01

Clinical trial

A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma

Status: Recruiting, Estimated PCD: 2030-09-01

Clinical trial

A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma

Status: Active (not recruiting), Estimated PCD: 2022-11-28

Clinical trial

Phase II Study of Patients With Recurrent Glioblastoma Multiforme Treated With Maximal Safe Neurosurgical Resection and Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent Electronic Brachytherapy System and Bevacizumab

Status: Terminated, Estimated PCD: 2024-04-24

Clinical trial

A Phase II Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) or Atezolizumab + Eribulin (AE) in Patients With Recurrent/Metastatic Inflammatory Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

A Phase I/II Study Exploring the Safety and Activity of Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

A Randomized Phase II Study Comparing Atezolizumab After Concurrent Chemo-radiotherapy With Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer

Status: Active (not recruiting), Estimated PCD: 2024-04-01

Clinical trial

Phase I/II Trial of Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV-unrelated Squamous Cell Carcinoma of the Head and Neck (HNSCC)

Status: , Estimated PCD: 2023-11-24

Clinical trial

Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy

Status: Recruiting, Estimated PCD: 2025-02-01

Clinical trial

An Open Label, Randomized, Phase III Trial, Evaluating Efficacy of Atezolizumab in Addition to One Year BCG (Bacillus CaLmette-Guerin) Bladder Instillation in BCG-naive Patients With High-risk Non-muscle Invasive Bladder cANcer

Status: Active (not recruiting), Estimated PCD: 2024-04-01

Clinical trial

Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion

Status: Recruiting, Estimated PCD: 2025-12-01

Clinical trial

A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2024-08-31

Clinical trial

Improving Public Cancer Care by Implementing Precision Medicine in Norway A Multi-cohort Phase 2 Treatment Clinical Study Investigating Efficacy of Approved Drugs Outside Indication in Patients With Advanced Cancer

Status: Recruiting, Estimated PCD: 2040-03-30

Clinical trial

Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Status: Active (not recruiting), Estimated PCD: 2025-04-01

Clinical trial

A Prospective, Randomized, Open Label Clinical Study Evaluating Efficacy and Safety of Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic Triple Negative Breast Cancer

Status: Recruiting, Estimated PCD: 2025-01-10

Clinical trial

Single-Arm Phase II-Study in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) With Poor Performance Status Receiving Atezolizumab-Carboplatin-Etoposide

Status: Active (not recruiting), Estimated PCD: 2024-04-01

Clinical trial

A Randomized Phase 2 Study of Atezolizumab With or Without Selinexor in Alveolar Soft Part Sarcoma (AXIOM)

Status: Recruiting, Estimated PCD: 2025-05-01

Clinical trial

Evaluation of Costs and Outcomes of the Implementation of Treatment Protocol Based on Rational Utilization of Anti-PD1 Agents in Patients With Non-small-cell Lung Cancer in the Brazilian Public Health System

Status: Completed, Estimated PCD: 2023-06-30

Clinical trial

FOLFOX Via Hepatic Artery Infusion Chemotherapy (HAI) Plus Systemic Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Patients With Initially Unresectable RAS-mutated Colorectal Cancer With Liver Metastases: A Prospective, Randomized, Controlled Clinical Study

Status: Recruiting, Estimated PCD: 2026-12-31

Clinical trial

The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer

Status: Completed, Estimated PCD: 2022-10-31

Clinical trial

A Phase Ib Adaptive Study Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

Status: Active (not recruiting), Estimated PCD: 2023-06-22

Clinical trial

A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas

Status: Completed, Estimated PCD: 2023-06-30

Clinical trial

A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Status: Recruiting, Estimated PCD: 2026-12-20

Clinical trial

DURABLE: Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and rEarrangements

Status: Recruiting, Estimated PCD: 2026-01-01

Clinical trial

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

Status: Recruiting, Estimated PCD: 2026-01-31

Clinical trial

A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)

Status: Recruiting, Estimated PCD: 2028-08-03

Clinical trial

A Phase III Randomized, Double-blinded Trial of Platinum-based Chemotherapy With or Without Atezolizumab Followed by Niraparib Maintenance With or Without Atezolizumab in Patients With Recurrent Ovarian, Tubal or Peritoneal Cancer and Platinum Treatment-free Interval (TFIp) >6 Months

Status: Active (not recruiting), Estimated PCD: 2024-01-01

Clinical trial

NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial

Status: Not yet recruiting, Estimated PCD: 2026-04-01

Clinical trial

Pirfenidone in Combination With Standard of Care Treatment in Patients With Advanced Liver Fibrosis. Multicenter, Open Trial Focused on Safety, Fibrosis Efficacy Evaluation, and Pharmacokinetic Data.

Status: Completed, Estimated PCD: 2020-08-31

Clinical trial

A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)

Status: Active (not recruiting), Estimated PCD: 2019-04-30

Clinical trial

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIME

Status: Terminated, Estimated PCD: 2020-12-10

Clinical trial

Phase II Trial of Primary Radiotherapy With Androgen Ablation With or Without Adjuvant Niraparib for Selected High-Risk Locoregional Prostate Cancer

Status: Recruiting, Estimated PCD: 2026-06-07

Clinical trial

A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib Tosilate Tablets or Bevacizumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Status: Not yet recruiting, Estimated PCD: 2026-01-01

Clinical trial

Randomized Phase II Study of FOLFOXIRI Plus Bevacizumab Plus Atezolizumab Versus FOLFOXIRI Plus Bevacizumab as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients.

Status: Completed, Estimated PCD: 2021-06-15

Clinical trial

A Phase II Multi-Center Trial of Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

Status: Active (not recruiting), Estimated PCD: 2024-12-20

Clinical trial

A Multicentre, Open-label, Phase I-II Study Evaluating the Combination of a MEK Inhibitor and a PDL1 Inhibitor in Pediatric and Adult Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma.

Status: Recruiting, Estimated PCD: 2026-02-01

Clinical trial

Phase II Trial of PARP Inhibitor Niraparib for Men With High Risk Prostate Cancer and DNA Damage Response Defects

Status: Recruiting, Estimated PCD: 2024-08-01

Clinical trial

Phase I Trial of Radiotherapy in Combination With Atezolizumab in Borderline Resectable and Unresectable Cutaneous Squamous Cell Carcinoma(cSCC)

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

Neo-Adjuvant Atezolizumab Prior to Definitive Surgical Resection of Regionally Metastatic Head &Amp; Neck Cutaneous Squamous Cell Carcinoma With an Unknown or Historic Primary Site: A Window Trial

Status: Terminated, Estimated PCD: 2022-05-02

Clinical trial

Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial (IMAGINE)

Status: Active (not recruiting), Estimated PCD: 2026-07-01

Clinical trial

Adjuvant Checkpoint Blockade Plus Radiation In Locally Advanced, Mismatch Repair Deficient/Microsatellite Instability-High (MMR-D/MSI-H) Endometrial Cancer

Status: Active (not recruiting), Estimated PCD: 2025-02-01

Clinical trial

An Open Label, Randomized Phase II Study Neoadjuvant Erdafitinib With or Without Atezolizumab in Cisplatin-Ineligible Patients With Muscle Invasive Bladder Cancer (NERA)

Status: Withdrawn, Estimated PCD: 2023-11-03

Clinical trial

A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene

Status: Not yet recruiting, Estimated PCD: 2027-07-13

Clinical trial

Pembrolizumab in Combination With Xelox Bevacizumab in Patients With Microsatellite Stable Mestatic Colorectal Cancer and a High Immune Infiltrate : a Proof of Concept Study

Status: Recruiting, Estimated PCD: 2024-09-30

Clinical trial

A Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response (DDR) Pathway Deficient Neoplasms (UF-STO-ETI-001)

Status: Completed, Estimated PCD: 2022-08-30

Clinical trial

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

Status: Recruiting, Estimated PCD: 2024-07-31

Clinical trial

A Phase II Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: HCRN GU17-295

Status: Terminated, Estimated PCD: 2022-03-08

Clinical trial

A Phase II Randomized Study of Atezolizumab Plus Multi-Kinase Inhibitor Versus Multi-Kinase Inhibitor Alone in Subjects With Unresectable, Advanced Hepatocellular Carcinoma Who Previously Received Atezolizumab Plus Bevacizumab

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

ALICE: A Randomized Placebo-controlled Phase II Study Evaluating Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer

Status: Completed, Estimated PCD: 2023-04-25

Clinical trial

Phase Ib Study With the Combination of LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients - The CoLBAt Trial

Status: Not yet recruiting, Estimated PCD: 2026-07-01

Clinical trial

Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

Status: Recruiting, Estimated PCD: 2025-03-01

Clinical trial

A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix

Status: Active (not recruiting), Estimated PCD: 2024-11-01

Clinical trial

Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma: A Multi-center, Open-label, Prospective Clinical Study

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Status: Active (not recruiting), Estimated PCD: 2023-09-30

Clinical trial

Atezolizumab/Carboplatin/Nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in Metastatic TTF-1 Negative Lung Adenocarcinoma

Status: Recruiting, Estimated PCD: 2025-10-01

Clinical trial

Phase III Randomized Multicenter Trial Comparing Continued Maintenance Therapy With the Bevacizumab + Taxane Versus Bevacizumab + Substituting Exemestane in Patients With Metastatic Breast Cancer or Locally Advanced With Estrogen Receptor Positive and Having at Least a Stable Disease After 16 to 18 Weeks of Treatment With Bevacizumab + Taxane.

Status: Terminated, Estimated PCD: 2014-06-01

Clinical trial

Randomized Phase II, 2-arm Study of Immunomodulation With Atezolizumab Concomitant With High Dose Radiation (SBRT) Versus SBRT Alone in Patients With Oligometastatic Sarcomas

Status: Recruiting, Estimated PCD: 2025-07-01

Clinical trial

Use of Bevacizumab in Trabeculectomy Surgery. A Prospective, 2 Centre, Randomized, Controlled Trial

Status: Completed, Estimated PCD: 2013-09-01

Clinical trial

Investigation of Antitumor Immune Response in Patients With Unresectable Hepatocellular Carcinoma Undergoing Proton Radiotherapy Combined With Atezolizumab and Bevacizumab

Status: Recruiting, Estimated PCD: 2028-09-30

Clinical trial

Exploratory Study of Irinotecan Liposomes Combined With Bevacizumab in Maintenance Therapy of Metastatic Colorectal Cancer

Status: Not yet recruiting, Estimated PCD: 2026-04-01

Clinical trial

A Multicenter Phase II Non-randomised Trial Assessing the Efficacy of DKN-01 Plus Atezolizumab in Patients With Advanced Mismatch Repair Proficient Oesophagogastric Cancer

Status: Recruiting, Estimated PCD: 2024-05-30

Clinical trial

A Single-arm, Phase II Study of Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in Resectable Non-small Cell Lung Cancer (NSCLC)

Status: Completed, Estimated PCD: 2022-10-01

Clinical trial

Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

Status: Withdrawn, Estimated PCD: 2023-08-07

Clinical trial

BEACON - A Phase II Study of Bevacizumab, Atezolizumab and Cobimetinib in Patients With Recurrent Platinum Resistant High Grade Serous Ovarian Cancer

Status: Active (not recruiting), Estimated PCD: 2024-02-28

Clinical trial

A Multi-center, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Serplulimab Plus Bevacizumab and Chemotherapy for EGFRm+ Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

Status: Recruiting, Estimated PCD: 2024-08-31

Clinical trial

AtezoCab: A Phase II Study of Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Non-Measurable Disease

Status: Recruiting, Estimated PCD: 2025-01-01

Clinical trial

ATTAMAGE-A1.: Phase I/II Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity MAGE-A1-Specific T-Cell Receptor (TCR) Combined With Atezolizumab in Patients With Metastatic MAGE-A1 Expressing Cancer

Status: Terminated, Estimated PCD: 2022-08-04

Clinical trial

A Phase II, Open-Labeled, Multi-Center, Randomized Controlled Trial of Vinblastine +/- Bevacizumab for the Treatment of Chemotherapy-Naïve Children With Unresectable or Progressive Low Grade Glioma (LGG)

Status: Active (not recruiting), Estimated PCD: 2024-07-31

Clinical trial

Bevacizumab Plus encoRAfenib-cetuximab in BRAF-V600E Mutated Metastatic Colorectal Cancer, a Phase II Study With a Safety lead-in Cohort, the BRAVE Trial

Status: Not yet recruiting, Estimated PCD: 2027-05-01

Clinical trial

Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction

Status: Completed, Estimated PCD: 2021-10-28

Clinical trial

Niraparib (PARP Inhibitor) Plus Dostarlimab (Anti-PD1) for Small Cell Lung Cancer (SCLC) and Other High-Grade Neuroendocrine Carcinomas (NEC)

Status: Active (not recruiting), Estimated PCD: 2025-05-30

Clinical trial

Prospective Single Arm, Single Center, Phase II Clinical Study of Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab Treatment System for Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional Therapy

Status: Not yet recruiting, Estimated PCD: 2025-07-31

Clinical trial

RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

Status: Recruiting, Estimated PCD: 2027-04-30

Clinical trial

A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer - a Pragmatic Trial

Status: Recruiting, Estimated PCD: 2025-01-31

Clinical trial

Phase 2 Trial of TGF-β2 Inhibition (OT-101) With Atezolizumab as Second-Line or Third-Line Therapy for Patients Previously Treated With Immunotherapy (+/- Chemotherapy) With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Status: Withdrawn, Estimated PCD: 2028-07-31

Clinical trial

Modulation of the FOLFIRI-based Standard First-line Therapy With Cetuximab, Controlled by Monitoring the RAS (Rat Sarcoma) Mutation Load by Liquid Biopsy in RAS-mutated mCRC (Metastatic Colorectal Cancer): A Randomized Phase II Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab (MoLiMoR)

Status: Active (not recruiting), Estimated PCD: 2024-07-22

Clinical trial

An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma

Status: Completed, Estimated PCD: 2023-03-30

Clinical trial

A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2024-04-30

Clinical trial

A Randomised, Open-label, Phase II, Dose/Schedule Optimisation Study of NUC-3373/Leucovorin/Irinotecan Plus Bevacizumab (NUFIRI-bev) Versus 5-FU/Leucovorin/Irinotecan Plus Bevacizumab (FOLFIRI-bev) for the Treatment of Patients With Previously Treated Unresectable Metastatic Colorectal Cancer

Status: Active (not recruiting), Estimated PCD: 2024-09-01

Clinical trial

A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer

Status: Active (not recruiting), Estimated PCD: 2025-03-31

Clinical trial

A Phase II, Open-label, Randomized-controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody Atezolizumab for the Treatment in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

Status: Completed, Estimated PCD: 2024-03-01

Clinical trial

Endocrine Therapy With or Without Anti-VEGF Therapy: A Randomized, Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865) for Women With Hormone Receptor-Positive Advanced Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2014-06-30

Clinical trial

A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers

Status: Active (not recruiting), Estimated PCD: 2024-09-30

Clinical trial

A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide, and Atezolizumab in Induction and With Atezolizumab in Maintenance Phase

Status: Recruiting, Estimated PCD: 2025-05-05

Clinical trial

An Open-Label, Phase II, Pre-Operative Study of Atezolizumab Plus Bevacizumab for Resectable Hepatocellular Carcinoma

Status: Recruiting, Estimated PCD: 2027-05-31

Clinical trial

A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial

Status: Recruiting, Estimated PCD: 2026-01-01

Clinical trial

Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver

Status: Recruiting, Estimated PCD: 2025-09-01

Clinical trial

A Multi-Center Trial of Androgen Suppression With Abiraterone aCetate, LEuprolide, PARP Inhibition and Stereotactic Body Radiotherapy (ASCLEPIuS): A Phase I/2 Trial in High Risk and Node Positive Prostate Cancer

Status: Recruiting, Estimated PCD: 2026-11-01

Clinical trial

Phase II Study Evaluating Holmium-166 TARE Followed by Maintenance Therapy in Liver Limited Unresectable Colorectal Cancer Patients After First-line Chemotherapy and Target Agents

Status: Recruiting, Estimated PCD: 2026-11-01

Clinical trial

IIT2022-05-Sankar-BELIEVE: Phase II Study of Bevacizumab in Combination With Chemoimmunotherapy and Maintenance Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases

Status: Not yet recruiting, Estimated PCD: 2026-09-28

Clinical trial

Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2014-08-01

Clinical trial

Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients With Advanced Small Cell Lung Cancer That Progressed Following Prior Therapy With Platinum-Based Chemotherapy.

Status: Recruiting, Estimated PCD: 2025-05-01

Clinical trial

A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours

Status: Recruiting, Estimated PCD: 2026-08-19

Clinical trial

A Phase II Open-label Multi-cohort Study Evaluating the Efficacy of Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

A Phase II Study of Intermittent Checkpoint Inhibitor Therapy in Patients With Advanced Urothelial Carcinoma

Status: Completed, Estimated PCD: 2022-08-08

Clinical trial

A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab

Status: Active (not recruiting), Estimated PCD: 2024-12-01

Clinical trial

A Phase II Trial of Atezolizumab (Anti-PDL1) With Carboplatin in Patients With Metastatic Triple Negative Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2022-11-30

Clinical trial

Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1)

Status: Completed, Estimated PCD: 2021-07-16

Clinical trial

A Pilot Phase I Study of Atezolizumab (MPDL3280A) in Combination With Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma

Status: Active (not recruiting), Estimated PCD: 2025-06-30

Clinical trial

Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a PDL-1 Inhibitor in Patients With Triple Negative Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2025-12-31

Clinical trial

Phase II Trial of Niraparib in Patients With Recurrent Glioma

Status: Terminated, Estimated PCD: 2023-11-14

Clinical trial

Pilot Study of Abemaciclib With Bevacizumab in Recurrent Glioblastoma Patients With Loss of CDKN2A/B or Gain or Amplification of CDK4/6

Status: Active (not recruiting), Estimated PCD: 2024-10-24

Clinical trial

A Phase II Study of Maintenance Vorolanib and Atezolizumab in Patients With Extensive-stage SCLC

Status: Active (not recruiting), Estimated PCD: 2022-08-18

Clinical trial

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors: An Open-label, Phase II, Single-arm, Multi-center Trial

Status: Recruiting, Estimated PCD: 2025-01-01

Clinical trial

A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients With Recurrent Glioblastoma Multiforme (GBM)

Status: Completed, Estimated PCD: 2017-09-01

Clinical trial

Phase I/II Trial of Niraparib/Selenium Combination Treatment in Patients With BRCA1/2-Wild Type Recurrent Platinum-Resistant Ovarian Cancer

Status: Not yet recruiting, Estimated PCD: 2026-11-27

Clinical trial

A Phase I/II Multicenter Study Combining Guadecitabine, a DNA Methyltransferase Inhibitor, With Atezolizumab, an Immune Checkpoint Inhibitor, in Patients With Intermediate or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Status: Active (not recruiting), Estimated PCD: 2024-11-30

Clinical trial

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Status: Recruiting, Estimated PCD: 2026-12-31

Clinical trial

Phase 1/2 Open-label Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies

Status: Active (not recruiting), Estimated PCD: 2024-06-01

Clinical trial

A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)

Status: Active (not recruiting), Estimated PCD: 2015-02-25

Clinical trial

Genotype-Directed Phase II Study Of Higher Dose Of Irinotecan In First-Line Metastatic Colorectal Cancer Patients Treated With Folfiri Plus Bevacizumab

Status: Active (not recruiting), Estimated PCD: 2027-06-01

Clinical trial

A Study of Bevacizumab, a Humanized Monoclonal Antibody Against Vascular Endothelial Growth Factor (VEGF), in Combination With Chemotherapy for Treatment of Osteosarcoma

Status: Completed, Estimated PCD: 2014-08-01

Clinical trial

Phase II Single Arm Study of Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

Status: Terminated, Estimated PCD: 2023-01-30

Clinical trial

Prospective Study of Stereotactic Radiosurgery Using Diffusion-Weighted Abnormality Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-line Chemotherapy

Status: Completed, Estimated PCD: 2016-12-01

Clinical trial

A Phase II Clinical Trial of Tiragolumab in Combination With Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

Status: Recruiting, Estimated PCD: 2025-09-30

Clinical trial

Pembrolizumab Plus Bevacizumab and Chemotherapy as First-Line Treatment for Advanced or Metastatic Non-Squamous NSCLC Patients With EGFR Exon 20 Insertion Mutation: An Open-Label, Single-Arm, Phase II Trial

Status: Recruiting, Estimated PCD: 2026-03-30

Clinical trial

A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma

Status: Active (not recruiting), Estimated PCD: 2021-10-06

Clinical trial

Combination of Talimogene Laherparepvec With Atezolizumab in Patients With Residual Breast Cancer After Standard Neoadjuvant Multi-agent Chemotherapy (PROMETEO TRIAL)

Status: Active (not recruiting), Estimated PCD: 2022-04-27

Clinical trial

Canadian Atezolizumab Precision Targeting for Immunotherapy Intervention

Status: Recruiting, Estimated PCD: 2026-10-01

Clinical trial

A Phase II, Single Arm Study of Atezolizumab + Bevacizumab in Women With Advanced, Recurrent or Persistent Endometrial Cancer

Status: Active (not recruiting), Estimated PCD: 2024-08-31

Clinical trial

Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

Status: Not yet recruiting, Estimated PCD: 2028-02-22

Clinical trial

A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer

Status: Active (not recruiting), Estimated PCD: 2024-10-21

Clinical trial

A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting

Status: Active (not recruiting), Estimated PCD: 2024-06-01

Clinical trial

A Phase II Trial of Atezolizumab + Carboplatin + Etoposide With Liver-Directed Radiotherapy (RT) in Extensive Stage Small Cell Lung Cancer (ES-SCLC) Patients With Liver Metastases

Status: Recruiting, Estimated PCD: 2024-02-01

Clinical trial

Halting Early Advancement of Residual Disease by Treatment With Bevacizumab and Atezolizumab in Ovarian Cancer

Status: Withdrawn, Estimated PCD: 2023-02-22

Clinical trial

Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin

Status: Active (not recruiting), Estimated PCD: 2022-09-20

Clinical trial

Phase II Trial of Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer (OU-SCC-STAR)

Status: Recruiting, Estimated PCD: 2025-07-01

Clinical trial

A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation

Status: Recruiting, Estimated PCD: 2026-10-31

Clinical trial

Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours

Status: Recruiting, Estimated PCD: 2025-05-01

Clinical trial

A Phase Ib/II, Dose Escalation and Dose Expansion Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma (HCC)

Status: Not yet recruiting, Estimated PCD: 2027-10-31

Clinical trial

KOrean Precision Medicine Networking Group Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

Status: Recruiting, Estimated PCD: 2025-09-01

Clinical trial

Hepatic Arterial Infusion Chemotherapy With FOLFOX Plus Atezolizumab and Bevacizumab for Patients With High-risk Hepatocellular Carcinoma: a Single-arm Phase 2 Trial

Status: Recruiting, Estimated PCD: 2024-06-01

Clinical trial

Candonilimab Plus Bevacizumab as Second-line Treatment for Patients With Advanced Hepatocellular Carcinoma Who Progressed on Atezolizumab Plus Bevacizumab: a Single Arm, Phase 2 Trial

Status: Withdrawn, Estimated PCD: 2023-03-31

Clinical trial

A Phase II Study of Niraparib and Dostarlimab With Radiation in Patients With Metastatic Pancreatic Cancer

Status: Completed, Estimated PCD: 2022-01-19

Clinical trial

A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Status: Terminated, Estimated PCD: 2017-08-31

Clinical trial

The Efficacy and Safety of Bevacizumab in Patients With Severe Covid-19: a Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial

Status: Recruiting, Estimated PCD: 2023-11-30

Clinical trial

Adjuvant Chemotherapy Combined With Targeted Therapy Versus Adjuvant Chemotherapy Alone in the Treatment of Stage T3-4N2 Colorectal Cancer:A Multicenter, Randomized, Phase III Clinical Trail

Status: Recruiting, Estimated PCD: 2030-04-01

Clinical trial

Pirfenidone Use in Asbestosis Patients: Efficacy and Prognosis

Status: Not yet recruiting, Estimated PCD: 2025-02-01

Clinical trial

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)

Status: Active (not recruiting), Estimated PCD: 2025-09-30

Clinical trial

A Randomized Phase 1/2 Trial Evaluating the Addition of Tolinapant to Weekly Paclitaxel With or Without Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer

Status: Not yet recruiting, Estimated PCD: 2028-02-09

Clinical trial

A Phase II Trial of the PD-1 Antibody Nivolumab in Combination With Hypofractionated Re-irradiation and Bevacizumab for Recurrent MGMT Methylated Glioblastoma

Status: Active (not recruiting), Estimated PCD: 2024-11-01

Clinical trial

A European, Multi-centre Phase II Trial of Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck (HNSCC)

Status: Active (not recruiting), Estimated PCD: 2024-03-01

Clinical trial

A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Status: Completed, Estimated PCD: 2022-03-29

Clinical trial

A Phase 2 Investigator Initiated Study to Determine the Efficacy and Safety of TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma

Status: Completed, Estimated PCD: 2020-04-04

Clinical trial

A Phase II Trial of Neoadjuvant Treatment Carboplatin-Pemetrexed-Bevacizumab Plus Atezolizumab for the Treatment of Locally Advanced and Potentially Resectable NSCLC Patients With EGFR Mutations

Status: Recruiting, Estimated PCD: 2024-12-30

Clinical trial

Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. A Proof-of-concept Study

Status: Recruiting, Estimated PCD: 2024-04-01

Clinical trial

TACE Combined With Bevacizumab in Patients With BCLC-B Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria: a Prospective Single-arm Phase II Study

Status: Not yet recruiting, Estimated PCD: 2025-05-31

Clinical trial

Phase II, Open Label, Single Arm Trial of Alectinib in Combination With Bevacizumab in Untreated and Previously Treated Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) With Positive ALK Driver Mutation

Status: Completed, Estimated PCD: 2022-08-01

Clinical trial

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

Status: Recruiting, Estimated PCD: 2026-04-01

Clinical trial

MegaMOST - A Multicenter, Open-label, Biology Driven, Phase II Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations /Characteristics in Advanced / Metastatic Tumors.

Status: Recruiting, Estimated PCD: 2026-02-01

Clinical trial

A Phase I Trial of an Immune Checkpoint Inhibitor Plus Stereotactic Ablative Radiotherapy in Patients With Inoperable Stage I Non-Small Cell Lung Cancer

Status: Active (not recruiting), Estimated PCD: 2020-01-22

Clinical trial

A Phase II Single-arm, Open-label Study of Atezolizumab and Derazantinib for Patients With Advanced Intrahepatic Cholangiocarcinoma With FGFR2

Status: Recruiting, Estimated PCD: 2025-12-01

Clinical trial

A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma

Status: Recruiting, Estimated PCD: 2025-06-01

Clinical trial

A Phase II Study Evaluating the Interest to Combine UCPVax a CD4 TH1-inducer Cancer Vaccine and Atezolizumab for the Treatment of Human PapillomaVirus Positive Cancers

Status: Active (not recruiting), Estimated PCD: 2024-09-01

Clinical trial

Induction by Docetaxel/Cisplatin/5-Fluorouracil (TCF) Prior to Radiotherapy With Concomintant Cetuximab in Locally Advanced Inoperable Head and Neck Tumours - a Methodical Trial

Status: Completed, Estimated PCD: 2010-01-19

Clinical trial

A Multicenter, Open-label, Phase II Study of AK104（an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in the Treatment of Recurrent or Metastatic Cervical Cancer

Status: Completed, Estimated PCD: 2024-02-28

Clinical trial

A Phase I Trial of Temsirolimus (CCI-779, Torisel) Combined With Cetuximab (Erbitux) in Cetuximab-Refractory Colorectal Cancer

Status: Completed, Estimated PCD: 2009-10-01

Clinical trial

A Phase I Study Of Irinotecan and Bevacizumab With Temozolomide in Children With Recurrent/Refractory Central Nervous System Tumors

Status: Completed, Estimated PCD: 2015-09-01

Clinical trial

A Phase II Study to Measure Response Rate and Toxicity of Neo-adjuvant Chemoradiotherapy With Oxaliplatin (OX) and Infusional 5-Fluorouracil (5-FU) Plus Cetuximab Followed by Post-Operative Docetaxel and Cetuximab in Patients With Operable Adenocarcinoma of the Esophagus

Status: Terminated, Estimated PCD: 2011-10-01

Clinical trial

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

Status: Withdrawn, Estimated PCD: 2022-12-14

Clinical trial

Pilot Study of Atezolizumab Plus PGV001, a Multipeptide Personalized Neoantigen Vaccine, in Patients With Locally Advanced or Metad or Metastatic Urothelial Cancer

Status: Completed, Estimated PCD: 2021-10-12

Clinical trial

A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Status: Recruiting, Estimated PCD: 2025-12-01

Clinical trial

A Randomized, Open-label Phase II/III Efficacy and Safety Study of Atezolizumab in Combination With FLOT Versus FLOT Alone in Patients With Gastric Cancer and Adenocarcinoma of the Oesophago-gastric Junction and High Immune Responsiveness (MO30039/MO43340) - The DANTE Trial

Status: Recruiting, Estimated PCD: 2027-05-31

Clinical trial

A Multicenter, Open Label, Phase II Basket Trial Exploring the Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors

Status: , Estimated PCD: 2024-12-01

Clinical trial

A Multi-Institutional, Open-Label, Randomized, Phase II Trial Of Ibrutinib In Combination With EGFR Inhibition Or PD-1 Inhibition In Patients With Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma

Status: Active (not recruiting), Estimated PCD: 2025-01-11

Clinical trial

A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile

Status: Recruiting, Estimated PCD: 2027-09-01

Clinical trial

A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies

Status: Active (not recruiting), Estimated PCD: 2024-11-21

Clinical trial

Feasibility Study of a Static Magnetic and Electric Field Device in Adults With Recurrent Glioblastoma and Their Partners

Status: Withdrawn, Estimated PCD: 2026-08-01

Clinical trial

EACH: A Randomised Phase II Study Evaluating the Safety and Anti-tumour Activity of the Combination of Avelumab and Cetuximab Relative to Avelumab Monotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Cancer

Status: Active (not recruiting), Estimated PCD: 2021-09-15

Clinical trial

Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab for Patients With Unresectable Colorectal Peritoneal Metastases

Status: Recruiting, Estimated PCD: 2025-01-01

Clinical trial

A Phase III Randomized Trial of Avelumab-cetuximab-Radiotherapy Versus Standards of Care in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Status: Active (not recruiting), Estimated PCD: 2027-12-01

Clinical trial

A Phase II Study of Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer

Status: Not yet recruiting, Estimated PCD: 2027-11-01

Clinical trial

Assessment of Response of Unresectable Hepatocellular Carcinoma to Combination Chemoembolization and Stereotactic Body Radiation Therapy

Status: Completed, Estimated PCD: 2022-01-01

Clinical trial

A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer

Status: Active (not recruiting), Estimated PCD: 2015-01-31

Clinical trial

Raltitrexed Combined With Irinotecan (SALIRI) Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer (mCRC) : an Open-label, Multi-center, and Prospective Study

Status: Recruiting, Estimated PCD: 2023-06-30

Clinical trial

A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) Big Ten Cancer Research Consortium BTCRC-LUN19-396

Status: Recruiting, Estimated PCD: 2024-06-01

Clinical trial

Atezolizumab Plus Bevacizumab for Patients With Advanced Hepatocellular Carcinoma (HCC) and Chronic Hepatitis B Virus (HBV) Infection

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

Status: Terminated, Estimated PCD: 2022-12-30

Clinical trial

A Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JS015 Combination Therapy in Patients With Advanced Solid Tumors

Status: Not yet recruiting, Estimated PCD: 2025-11-30

Clinical trial

A Window of Opportunity Trial of Cetuximab in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

Status: Completed, Estimated PCD: 2022-03-15

Clinical trial

Phase II Trial of Induction Immunotherapy With Atezolizumab for Patients With Unresectable Stage IIIA and IIIB NSCLC Eligible for Chemoradiotherapy With Curative Intent.

Status: Completed, Estimated PCD: 2020-06-01

Clinical trial

A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors

Status: Completed, Estimated PCD: 2017-12-18

Clinical trial

Randomized Phase 3 Study on the Optimization of Bevacizumab With mFOLFOX/mOXXEL in the Treatment of Patients With Metastatic Colorectal Cancer

Status: Completed, Estimated PCD: 2015-12-01

Clinical trial

A Phase I Trial of MR-Guided Dose-Escalated Hypofractionated Adaptive Radiation Therapy and Immunotherapy in Primary Metastatic or Very Locally Advanced Patients With Head and Neck Cancer

Status: Recruiting, Estimated PCD: 2024-12-30

Clinical trial

A Multi-center Phase II Study of Combining Cabozantinib and Atezolizumab as the 1st Line Therapy for PD-L1 Negative Advanced/Metastatic NSCLC (Cabatezo-1)

Status: Not yet recruiting, Estimated PCD: 2026-06-01

Clinical trial

Study of Atezolizumab in Combination With Carboplatin + Paclitaxel +Bevacizumab vs With Pemetrexed + Cisplatin or Carboplatin With Stage IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER With EGFR(+) or ALK(+)

Status: Active (not recruiting), Estimated PCD: 2023-03-11

Clinical trial

Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced, Oligoprogressive NSCLC After Upfront Chemotherapy and Anti-PD1 Immunotherapy: A Multicentre, Single Arm, Phase II Study

Status: Active (not recruiting), Estimated PCD: 2023-01-23

Clinical trial

Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Microsatellite Stable Metastatic Colorectal Cancer

Status: Completed, Estimated PCD: 2024-01-30

Clinical trial

A Randomized Multicenter Clinical Trial for Patient With Multi-organ, Colorectal Cancer Metastases Comparing the Combination of Chemotherapy and Maximal Tumor Debulking Versus Chemotherapy Alone.

Status: Recruiting, Estimated PCD: 2023-07-01

Clinical trial

An Open-Label, Multicenter Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

A Phase 1b/2 Trial of Preoperative Niraparib, Dostarlimab, and Hypofractionated Radiotherapy for the Treatment of Locally-advanced Rectal Cancers.

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

Study of Intratumoral Injection of Dendritic Cells After High-Dose Conformal External Beam Radiotherapy in Patients With Unresectable Liver Cancer

Status: Recruiting, Estimated PCD: 2027-08-31

Clinical trial

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)

Status: Recruiting, Estimated PCD: 2025-04-09

Clinical trial

A Non-comparative Randomized Phase II Trial Evaluating the Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced Non-squamous NSCLC Progressing After Immunotherapy and Chemotherapy

Status: Recruiting, Estimated PCD: 2025-09-01

Clinical trial

A Randomized Open-label Phase 3 Trial Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer

Status: Active (not recruiting), Estimated PCD: 2023-12-01

Clinical trial

A Phase 2 Study of Dostarlimab in Combination With Cobolimab in Advanced Cervical Cancer

Status: Recruiting, Estimated PCD: 2026-02-01

Clinical trial

A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2014-01-07

Clinical trial

Multicenter, Randomized Trial to Evaluate Efficacy and Safety of Bevacizumab in Combination With Endocrine Treatment vs Endocrine Alone, in Postmenopausal With Advanced or Metastatic Cancer With Indication of Hormonotherapy as First-line

Status: Completed, Estimated PCD: 2013-12-01

Clinical trial

A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined With Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients With Extensive-Stage Small Cell Lung Cancer

Status: Not yet recruiting, Estimated PCD: 2026-01-31

Clinical trial

Phase II Study of Irinotecan Liposomes Combined With 5-FU/LV+ Bevacizumab in First-line Treatment of Metastatic Colorectal Cancer

Status: Not yet recruiting, Estimated PCD: 2026-04-01

Clinical trial

Phase 1/2 Study of TPX-0005 (Repotrectinib) in Combination With Chemotherapy in Pediatric and Young Adult Subjects With Advanced or Metastatic Solid Tumors and Primary Central Nervous System Tumors

Status: Recruiting, Estimated PCD: 2028-08-01

Clinical trial

Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma, a Phase 2b Randomized Trial

Status: Terminated, Estimated PCD: 2024-03-08

Clinical trial

An Open-label, Multicenter, Randomized Phase 2 Study of the ATR Inhibitor Tuvusertib in Combination With the PARP Inhibitor Niraparib or the ATM Inhibitor Lartesertib in Participants With BRCA Mutant and/or Homologous Recombination deﬁciency (HRD)-Positive Epithelial Ovarian Cancer That Progressed on Prior PARP Inhibitor Therapy (DDRiver EOC 302)

Status: Not yet recruiting, Estimated PCD: 2028-01-10

Clinical trial

A Study to Evaluate the Efficacy and Safety of the Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Child-Pugh B and/or ECOG PS 2 Unresectable Hepatocellular Carcinoma

Status: Recruiting, Estimated PCD: 2023-11-01

Clinical trial

A Multicentric, Single Arm, Phase II Trial Assessing the Efficacy of Niraparib as First Line Therapy for Patients With Metastatic Homologous Repair-deficient Pancreatic Cancer

Status: Recruiting, Estimated PCD: 2026-01-15

Clinical trial

A Phase I/IB Study of Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Patients With Metastatic Triple Negative Breast Cancer

Status: Completed, Estimated PCD: 2023-01-21

Clinical trial

A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Status: Active (not recruiting), Estimated PCD: 2026-12-31

Clinical trial

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer

Status: Recruiting, Estimated PCD: 2024-11-30

Clinical trial

Multi-arm, Phase II Clinical Study of Intraperitoneal Injection of Recombinant Human Tumor Necrosis Factor, Bevacizumab Monoclonal Antibody, and Serplulimab for the Treatment of Malignant Ascites Patients With Standard Therapy Failure

Status: Recruiting, Estimated PCD: 2026-12-31

Clinical trial

Paclitaxel Plus Cetuximab for the Treatment of Recurrent and/or Metastatic Head and Neck Cancer After First-line Checkpoint Inhibitor Failure: A Multicenter, Single Arm Study

Status: Recruiting, Estimated PCD: 2023-12-01

Clinical trial

Phase II Trial of Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With Metastatic Colorectal Cancer

Status: Recruiting, Estimated PCD: 2025-10-01

Clinical trial

A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma

Status: Completed, Estimated PCD: 2014-04-01

Clinical trial

A MULTICENTER STUDY IN PATIENTS WITH STAGE III-IV EPITHELIAL OVARIAN CANCER TREATED WITH CARBOPLATIN/PACLITAXEL WITH BEVACIZUMAB: CLINICAL AND BIOLOGICAL PROGNOSTIC FACTORS

Status: Active (not recruiting), Estimated PCD: 2024-12-01

Clinical trial

A Pilot Study of Neoadjuvant Stereotactic Beam Radiation Therapy Followed by Atezolizumab and Bevacizumab in Resectable Hepatocellular Carcinoma

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

A Phase II Study of the Anti-PDL1 Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid to Investigate Safety and Efficacy of This Combination in Recurrent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma

Status: Completed, Estimated PCD: 2021-06-01

Clinical trial

Efficacy Analysis of Anti-vascular Endothelial Growth Factor (VEGF) Drugs Combined With Micropulse Laser in the Treatment of Diabetic Macular Edema

Status: Recruiting, Estimated PCD: 2023-12-01

Clinical trial

Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

Status: Recruiting, Estimated PCD: 2025-08-20

Clinical trial

Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2027-06-01

Clinical trial

A Phase 1b Study to Evaluate HMBD-001 in Combination With Docetaxel With or Without Cetuximab in Participants With Advanced Squamous Non-small Cell Lung Cancers

Status: Recruiting, Estimated PCD: 2026-04-01

Clinical trial

Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab (Tecentriq®) in Local Head and Neck Squamous Cell Carcinoma (the PIONEER Trial)

Status: Completed, Estimated PCD: 2024-03-14

Clinical trial

Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line

Status: Active (not recruiting), Estimated PCD: 2023-12-01

Clinical trial

Phase II Study Evaluating the Interest of the Re-introduction of Pemetrexed and Platinum (Cisplatin or Carboplatin) With Prolonged Angiogenic Blocking by Bevacizumab in Non Squamous Non Small Cell Lung Cancer of Advanced Stage.

Status: Completed, Estimated PCD: 2016-01-01

Clinical trial

A Prospective, Multicenter Phase II Clinical Study of Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB Driver Gene-negative Non-small Cell Lung Cancer (NSCLC)

Status: Recruiting, Estimated PCD: 2024-06-01

Clinical trial

A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Status: Recruiting, Estimated PCD: 2025-09-15

Clinical trial

Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients

Status: Active (not recruiting), Estimated PCD: 2015-01-01

Clinical trial

A Phase 1, Open-label, Multicenter Study of SYNB1891 Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors and Lymphoma Alone and in Combination With Atezolizumab

Status: Terminated, Estimated PCD: 2021-12-09

Clinical trial

A Phase II Trial of Atezolizumab Plus Induction Chemotherapy (CT) Plus Chemo-radiotherapy and Atezolizumab Maintenance Therapy in Non-resectable Stage IIIA-IIIB Non-small Cell Lung Cancer (NSCLC) Patients

Status: Recruiting, Estimated PCD: 2026-11-15

Clinical trial

An Observational Study to Evaluate the Microbiome as a Biomarker of Efficacy and Toxicity in Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy

Status: Recruiting, Estimated PCD: 2024-07-08

Clinical trial

A Phase II Study of Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-139

Status: Terminated, Estimated PCD: 2021-12-16

Clinical trial

A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer

Status: Completed, Estimated PCD: 2020-10-01

Clinical trial

A Phase 2 Intervention Study: Detection of Early Esophageal Neoplastic Lesions by Quantified Fluorescence Molecular Endoscopy Using Oral and Topical Administration of Bevacizumab-800CW and Cetuximab-800CW

Status: Not yet recruiting, Estimated PCD: 2024-12-01

Clinical trial

Efficacy and Safety of Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy for Refractory Metastatic Colorectal Cancer: a Retrospective Study

Status: Completed, Estimated PCD: 2022-10-31

Clinical trial

Pifenidone is Used to Reduce Radiation Lung Injury in Lung Cancer Patients Previously Treated With Immune Checkpoint Inhibitors: A Single-arm, Open-label, Phase II Study

Status: Recruiting, Estimated PCD: 2025-03-31

Clinical trial

A Multicentric Randomized Phase II/III Evaluating TSR-042 (Anti-PD-1 mAb) in Combination With Niraparib (Parpi) Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy

Status: Active (not recruiting), Estimated PCD: 2024-12-01

Clinical trial

Phase 2 Single Agent Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia (GTN)

Status: Withdrawn, Estimated PCD: 2026-12-01

Clinical trial

An Open-label Phase 1 of Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Platinum Resistant Epithelial Ovarian Cancer

Status: Active (not recruiting), Estimated PCD: 2021-03-11

Clinical trial

Does Avastin Change Evolution in Juxtafoveal Telangiectasias?

Status: Withdrawn, Estimated PCD: 2006-09-01

Clinical trial

Prevention of Post-photocoagulation Macular Edema by Intravitreal Bevacizumab.

Status: Withdrawn, Estimated PCD: 2008-12-01

Clinical trial

Phase III Study Comparing the Efficacy of Paclitaxel-bevacizumab With Docetaxel in 2nd or 3rd Line of Treatment of Non Squamous Non Small Cells Lung Cancer

Status: Completed, Estimated PCD: 2015-12-01

Clinical trial

A Phase I/II Study of Bomedemstat Combined With Maintenance Immunotherapy for Patients With Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Status: Active (not recruiting), Estimated PCD: 2023-08-03

Clinical trial

Candonilimab Plus Bevacizumab as Second-line Treatment for Patients With Advanced Hepatocellular Carcinoma Who Progressed on Atezolizumab Plus Bevacizumab: a Single Arm, Phase 2 Trial

Status: Recruiting, Estimated PCD: 2024-01-01

Clinical trial

A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer

Status: Completed, Estimated PCD: 2015-07-12

Clinical trial

An Open-Label, Multicenter, Phase I/II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Escalating Doses of Mosunetuzumab (BTCT4465A) as a Single Agent and Combined With Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Status: Active (not recruiting), Estimated PCD: 2025-11-15

Clinical trial

Phase II Trial of Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

A Multicenter Randomized Phase III Study for Recurrent Glioblastoma Comparing Bevacizumab Alone With Dose-dense Temozolomide Followed by Bevacizumab (JCOG1308C, RE-GEND-pIII)

Status: Active (not recruiting), Estimated PCD: 2025-11-10

Clinical trial

A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

Status: Recruiting, Estimated PCD: 2024-04-01

Clinical trial

A Phase Ia/II, Single Arm Trial on the Efficacy of Vemurafenib in Combination With Irinotecan and Cetuximab in BRAF V600E-Mutant Metastatic Colorectal Cancer

Status: Completed, Estimated PCD: 2021-12-31

Clinical trial

An Open-label, Multicentric, Phase Ib/II Study to Assess the Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to Niraparib in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With Niraparib Since at Least 6 Months

Status: Recruiting, Estimated PCD: 2023-10-01

Clinical trial

FASTing-like Approach to Improve the Efficacy of Maintenance IMMunotherapy in Extensive-stage Small Cell Lung Cancer Patients Not Progressing on Chemoimmunotherapy Induction: the FASTIMMUNE Trial

Status: Not yet recruiting, Estimated PCD: 2025-01-01

Clinical trial

Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

Randomized Phase 2 Trial Of Two Chemotherapy Regimens Plus Or Minus Bevacizumab In Patients With Well Differentiated Pancreatic Neuroendocrine Tumors

Status: Active (not recruiting), Estimated PCD: 2028-12-01

Clinical trial

A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Status: Recruiting, Estimated PCD: 2025-03-01

Clinical trial

An Open-Label, Single Arm, Phase II Trial of Niraparib in Combination With Anlotinib in Patients With Platinum-Resistant Recurrent or Platinum-Refractory Clear Cell Ovarian Cancer.

Status: Completed, Estimated PCD: 2023-01-01

Clinical trial

An Open-label, Randomized Study to Assess the Relative Bioavailability (BA) and Bioequivalence (BE) of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

Status: Active (not recruiting), Estimated PCD: 2021-10-15

Clinical trial

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Status: Active (not recruiting), Estimated PCD: 2025-04-02

Clinical trial

A Multicenter, Randomized, Double-Blind Trial in Subjects With Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)

Status: Completed, Estimated PCD: 2020-02-10

Clinical trial

Real-world Data From a Multi-center Study: Insights to the Effectiveness and Safety in Patients With Ovarian Cancer Receiving Niraparib as First-line Maintenance Therapy

Status: Completed, Estimated PCD: 2022-12-31

Clinical trial

Phase II Study of Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers: A Proof of Concept Study

Status: Not yet recruiting, Estimated PCD: 2026-07-01

Clinical trial

Phase II Study of BEvacizumab (Avastin) in Combination With Atezolizumab or Atezolizumab (Tencentriq) and Cobimetinib (Cotellic) in Patients With Untreated Melanoma Brain Metastases (TACo-BEAT-MBM)

Status: Active (not recruiting), Estimated PCD: 2026-06-30

Clinical trial

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Status: Active (not recruiting), Estimated PCD: 2024-11-15

Clinical trial

A Single-armed Phase Ⅱ Study of Bevacizumab Maintenance Therapy After Chemoradiotherapy for Locally Advanced Lung Adenocarcinoma

Status: Completed, Estimated PCD: 2021-12-10

Clinical trial

Phase IB Trial of Niraparib and TSR-042 in Patients With BRCA-Mutated Breast, Pancreas or Ovary Cancer

Status: Recruiting, Estimated PCD: 2024-09-01

Clinical trial

Study to Investigate Outcome of Individualized Treatment Based on Pharmacogenomic Profiling & Ex Vivo Drug Sensitivity Testing of Patient-derived Organoids in Patients With Metastatic Colorectal Cancer

Status: Recruiting, Estimated PCD: 2038-12-31

Clinical trial

Neoadjuvant Atezolizumab in Patients With Non-Metastatic Resectable High-Risk Cutaneous Melanoma

Status: Recruiting, Estimated PCD: 2025-12-01

Clinical trial

Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I)

Status: , Estimated PCD: 2028-01-30

Clinical trial

Phase I/II Trial Of Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab (Avastin) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma.

Status: Recruiting, Estimated PCD: 2025-10-01

Clinical trial

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

Status: Recruiting, Estimated PCD: 2024-11-01

Clinical trial

Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): "The APA Trial".

Status: Active (not recruiting), Estimated PCD: 2019-12-12

Clinical trial

Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer: a Prospective, Multicenter, Single-arm Study

Status: Recruiting, Estimated PCD: 2025-03-01

Clinical trial

A Multicenter,Open-label,Exploratory Study of QL1706 Plus Nab-paclitaxel and Gemcitabine With or Without Bevacizumab as First-line Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Status: Not yet recruiting, Estimated PCD: 2025-04-15

Clinical trial

Phase II Study of Bevasizumab in the Management of Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis

Status: Recruiting, Estimated PCD: 2025-12-30

Clinical trial

An Open Label Phase II Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors

Status: , Estimated PCD: 2024-12-01

Clinical trial

A Pilot Randomized Tissue-Based Study Evaluating Anti-PD1 Antibody or Anti-PD1 + Bevacizumab or Anti-PD1 + Anti-CTLA-4 in Patients With Metastatic Renal Cell Carcinoma Who Are Eligible for Cytoreductive Nephrectomy, Metastasectomy or Post-Treatment Biopsy

Status: Active (not recruiting), Estimated PCD: 2025-11-30

Clinical trial

A Phase II, Single Arm Study of CarbopLatin Plus Etoposide With Bevacizumab and Atezolizumab in Patients With exTEnded-disease Small-cell Lung Cancer (SCLC)

Status: Active (not recruiting), Estimated PCD: 2023-06-01

Clinical trial

Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer

Status: Active (not recruiting), Estimated PCD: 2026-04-30

Clinical trial

A Single Arm Phase II Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)

Status: Terminated, Estimated PCD: 2022-09-25

Clinical trial

Phase Ib Study to Evaluate Humanized CD19-Specific CAR T Cells Following Lymphodepleting Chemotherapy in Adult Patients With Relapsed/Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia

Status: Recruiting, Estimated PCD: 2025-08-06

Clinical trial

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria: A Feasibility Study

Status: Recruiting, Estimated PCD: 2027-04-30

Clinical trial

Randomized Phase II Trial of Neoadjuvant and Adjuvant Atezolizumab With or Without Tiragolumab in Conjunction With Chemoradiotherapy for Unresectable Stage III NSCLC

Status: Recruiting, Estimated PCD: 2025-08-01

Clinical trial

Evaluate the Efficacy and Safety of Ensartinib and Bevacizumab in Patients With Advanced, ALK-Rearranged Combined With TP53 Mutation, Non-Small Cell Lung Cancer: A Prospective, Open-label, Multi-center, Single-arm, Phase II Trial

Status: Recruiting, Estimated PCD: 2024-06-30

Clinical trial

Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas

Status: Active (not recruiting), Estimated PCD: 2025-07-31

Clinical trial

Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Status: Active (not recruiting), Estimated PCD: 2025-11-30

Clinical trial

A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications

Status: Active (not recruiting), Estimated PCD: 2026-03-31

Clinical trial

Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer

Status: Recruiting, Estimated PCD: 2026-12-30

Clinical trial

Efficacy, Safety and Predictive Indicators of Immunosuppressant Combined With Pirfenidone in the Treatment of Connective Tissue Disease-related Interstitial Lung Disease (CTD-ILD)

Status: Active (not recruiting), Estimated PCD: 2024-06-01

Clinical trial

Phase 2 and Biomarker Trial of Anti-TIGIT and Anti-PDL1 in Patients With Recurrent Glioblastoma

Status: Not yet recruiting, Estimated PCD: 2025-07-01

Clinical trial

Phase II Clinical Trial to Evaluate the Efficacy and Safety of First Line Atezolizumab in Combination With Paclitaxel and Bevacizumab (Avastin®) in Patients With Advanced or Metastatic Triple-negative Breast Cancer

Status: Completed, Estimated PCD: 2023-12-07

Clinical trial

A Phase II Study of Niraparib in Combination With EGFR Inhibitor Panitumumab in Patients With Advanced Colorectal Cancer

Status: Active (not recruiting), Estimated PCD: 2024-10-31

Clinical trial

A Randomised Phase II Trial Comparing the Efficacy of Single-fraction or Multi-fraction SABR (Stereotactic Ablative Body Radiotherapy) With AteZolizumab in Patients With Advanced Triple nEgative Breast Cancer

Status: Completed, Estimated PCD: 2023-06-22

Clinical trial

Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma

Status: Not yet recruiting, Estimated PCD: 2026-01-01

Clinical trial

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapies; An Observational Prospective Study

Status: Recruiting, Estimated PCD: 2024-07-01

Clinical trial

Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer: A Marker Based Phase II Trial

Status: Active (not recruiting), Estimated PCD: 2024-12-01

Clinical trial

Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)

Status: Recruiting, Estimated PCD: 2025-10-31

Clinical trial

MPDL3280A Treatment in Patients With Locally Advanced or Metastatic Solid Tumors After or During Investigational Imaging

Status: Active (not recruiting), Estimated PCD: 2023-09-19

Clinical trial

PANOVA-4: Pilot, Single Arm Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Status: Recruiting, Estimated PCD: 2026-08-01

Clinical trial

Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers

Status: Completed, Estimated PCD: 2023-04-24

Clinical trial

Immunotherapy in Combination With Ablative Radiosurgery to Ultra-high DoSes (ICARUS): A Phase I Dose-escalation Radiosurgery Study in Metastatic Cancers

Status: Not yet recruiting, Estimated PCD: 2027-07-01

Clinical trial

Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (aPDL1) in Combination With Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma (GBM)

Status: Active (not recruiting), Estimated PCD: 2025-06-30

Clinical trial

Phase I-II Study to Evaluate the Safety, Tolerability, and Efficacy of Lurbinectedin and Dostarlimab in Patients With Advanced/Recurrent Endometrial Cancer With Disease Progression Following Previous Platinum Chemotherapy Therapy

Status: Not yet recruiting, Estimated PCD: 2024-05-01

Clinical trial

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS- BREAST CANCER)

Status: Recruiting, Estimated PCD: 2026-04-30

Clinical trial

Phase II Evaluation of Cetuximab (C225) Combined With Induction Paclitaxel and Carboplatin Followed by C225, Paclitaxel, Carboplatin, and Radiation for Stage III/IV Operable Squamous Cancer of the Head and Neck

Status: Completed, Estimated PCD: 2010-02-01

Clinical trial

A Phase II, Single-Arm Open-Label Study of the Combination of Atezolizumab and Bevacizumab in Rare Solid Tumors

Status: Active (not recruiting), Estimated PCD: 2025-09-30

Clinical trial

A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers

Status: Active (not recruiting), Estimated PCD: 2024-09-01

Clinical trial

Phase II Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

Status: Active (not recruiting), Estimated PCD: 2019-11-13

Clinical trial

Randomized Phase II Study of Platinum-Taxane-Cetrelimab Induction Followed by Niraparib Plus or Minus Cetrelimab Maintenance in Men With Aggressive Variant Prostate Cancers

Status: Active (not recruiting), Estimated PCD: 2025-12-31

Clinical trial

Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Status: Active (not recruiting), Estimated PCD: 2023-06-01

Clinical trial

Reirradiation (Re-RT) and Niraparib (NIRA) in Patients With Recurrent Glioblastoma (rGBM)

Status: Withdrawn, Estimated PCD: 2023-10-13

Clinical trial

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Status: Terminated, Estimated PCD: 2023-09-27

Clinical trial

Continuous ReAssessment With Flexible ExTension in Rare Malignancies - CRAFT: The NCT-PMO-1602 Phase II Trial

Status: Recruiting, Estimated PCD: 2025-06-30

Clinical trial

Atezolizumab With Platinum and Etoposide Chemotherapy Followed by Cystectomy for Patients With Localized Small Cell Neuroendocrine Bladder Cancer

Status: Recruiting, Estimated PCD: 2025-06-01

Clinical trial

Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting

Status: Recruiting, Estimated PCD: 2026-04-01

Clinical trial

Phase II Study of Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

Status: Recruiting, Estimated PCD: 2026-07-01

Abstract

Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome.

Org: Niguarda Cancer Center, Laboratory of Experimental Hematology, Clinic of Hematology, Ente Ospedaliero Cantonale, Universita’ della Svizzera italiana,

Abstract

FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study.

Org: Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa & Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, Oncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli–IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy, Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, Pisa, Italy, Department of Oncology and Palliative Care, Cardinale G Panico, Tricase City Hospital, Tricase, Italy,

Abstract

First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

Org: Sackler School of Medicine, Hospital Universitario Fundación Jiménez Díaz, McGill University and MUHC, Sungkyunkwan University School of Medicine, Hospital Germans Trias i Pujol,

Abstract

SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC).

Org: University of Virginia, Charlottesville, VA, USA, Fred Hutchinson Cancer Research Center, Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Levine Cancer Institute,

Abstract

Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with metastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS final analysis.

Org: Gregorio Marañón University General Hospital, IRCCS Istituto Romagnolo per lo Studio dei Tumori, Institute of Oncology Ljubljana, Roche Products Limited, Roche,

Abstract

Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation.

Org: Sun Yat-sen University Cancer Center, MD Anderson Cancer Center, UT Southwestern Medical Center, Genentech, Roche (China) Holding Ltd.,

Abstract

Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC).

Org: City of Hope Comprehensive Cancer Center, Roche (China) Holding Ltd., Asan Medical Center, Genentech, Roche Products Ltd.,

Abstract

Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.

Org: Dana-Farber Cancer Institute, Gustave Roussy Cancer Center, Clinical Hospital No. 1 of the Poznan University of Medical Sciences, Memorial Sloan Kettering Cancer Center, Hospital Universitario 12 de Octubre,

Abstract

Molecular profiling of ctDNA from NCI-MATCH patients enrolled for treatment with mTOR1/2 inhibitor sapanisertib (arm M) and the Hedgehog pathway inhibitor vismodegib (arm T).

Org: Illumina, Inc., Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, Vilnius, Lithuania, Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD,

Abstract

Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the AtezoTRIBE study.

Org: University of Pisa, Pisa, Italy, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana and Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, Charité Universitätsmedizin Berlin, Berlin, Germany, Oncology Unit 1, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy, Department of Medical Oncology, University Campus Biomedico, Roma, Italy, Division of Clinical Pharmacology and Oncology, Department of Health Sciences, School of Psychology, University of Florence, Florence, Italy, University of Pisa, Pisa, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS Padua, Padua, Italy, U.O.C. Oncologia Medica, Presidio Ospedaliero Livorno, Livorno, Italy, Hämatologisch Onkologische Praxis Eppendorf (HOPE) and Universitäres Cancer Center Hamburg, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, Department of Oncology, Istituto Scientifico San Raffaele IRCSS, Milan, Italy, CdC Poliambulanza, Brescia, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS, Padua, Italy, IRCSS-CRO Aviano, Department of Clinical Oncology, Aviano, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Martin Luther University, Halle, Germany, Azienda Ospedaliera Universitaria Pisana, Università degli Studi di Trento, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,

Abstract

Salvage ipilimumab plus nivolumab in advanced hepatocellular carcinoma after prior anti-PD-(L)1 blockade.

Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Hospital, University of Texas Southwestern Medical Center, Division of Digestive and Liver Diseases, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH,

Abstract

Association between pCR, TILs, and Ki-67 at baseline and after 2 weeks in patients with triple-negative breast cancer (TNBC) treated with atezolizumab and chemotherapy +/- a preceding atezolizumab monotherapy window: A translational analysis of the neoMono trial.

Org: Palleos Healthcare, Red Cross Hospital Munich, Caritas-Klinikum Saarbrücken, Hematological/Oncological Practise,

Abstract

EphrinB2 (B2) expression predicts poor response to PD1/L1 antibodies (Ab) in metastatic urothelial carcinoma (mUC).

Org: University of Southern California Marshall School of Business, Vasgene Therapeutics, Inc, Rutgers University, Dana-Farber Cancer Institute, University of Colorado Cancer Center Anschutz Medical Campus,

Abstract

Leveraging innate immunity with AFM24, a novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager: Interim results for the non-small cell lung cancer (NSCLC) cohort.

Org: Affimed Inc., Samsung Medical Center, INCLIVA, Biomedical Research Institute, Vall d'Hebron Institute of Oncology, Affimed,

Abstract

IMpower010: Exploratory analysis of disease-free survival by KRAS status in patients with stage II-IIIA NSCLC treated with adjuvant atezolizumab vs best supportive care.

Org: Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, LungenClinic, Grosshansdorf, Germany, German Center of Lung Research, Genentech Inc., Stanford University School of Medicine/Stanford Cancer Institute,

Abstract

Real-world data: Clinical characteristics and outcomes of patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab in Veteran Health Administration.

Org: University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center-San Antonio, South Texas Veterans Health Care System, University of Texas Health San Antonio Cancer Center,

Abstract

An interventional study of the impact of digital patient monitoring (DPM) on health outcomes, healthcare resource utilization, and feasibility of a combination with at-home treatment (tx) for delivery of systemic anticancer tx in clinical practice.

Org: Lung cancer Europe, F. Hoffmann-La Roche Ltd, Hospital Clínic de Barcelona, IDIBAPS, IDIBAPS, Universidad de Barcelona,

Abstract

Evaluating racial disparities for patients with advanced hepatocellular carcinoma (HCC) receiving first line immunotherapy within an equal access system.

Org: The University of Texas Health Science Center-San Antonio, UTHSCSA, University of Texas Health Science Center at San Antonio, South Texas Veterans Health Care System, University of Texas Health San Antonio Cancer Center,

Abstract

Time-dependent efficacy of immune checkpoint inhibitors in the treatment of metastatic cancers: A meta-analysis.

Org: UPR "Chronotherapy, Cancers and Transplantation", Paris-Saclay University, Villejuif, France, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, North Wales Cancer Centre, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, United Kingdom, Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom, Department of Thoracic and Medical Oncology, Avicenne AP-HP, Université Sorbonne Paris Nord, Bobigny, France,

Abstract

Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.

Org: Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital Universitario Son Espases, Hospital Arnau de Vilanova; GEICAM Spanish Breast Cancer Group,

Abstract

A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA).

Org: Mass General Cancer Center, Mayo Clinic, University of California Irvine, Duke University Medical Center, The Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA,

Abstract

First in class TLR7/8 agonist BDB001 combined with atezolizumab and stereotactic body radiation therapy in patients with advanced pancreatic adenocarcinoma: Results from the AGADIR study.

Org: Department of Medical Oncology, Institute Bergonié Cancer Center, Bordeaux, France, Department of Radiation Oncology, Institut Bergonie, Bordeaux, France, Institut Paoli-Calmettes, Marseille, France, Early clinical unit CLIP2 INCA, Centre GF LECLERC, Dijon, France, Medical oncology Department, Institut Bergonié, Bordeaux, France,

Abstract

STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer.

Org: David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School, Exelixis, Inc.,

Abstract

Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting fusion protein, in combination with atezolizumab in patients with advanced solid tumors.

Org: University of Pittsburgh Medical Center, Sidney Kimmel Cancer Center at Thomas Jefferson University, UPMC Hillman Cancer Center, KAHR Medical Ltd., University of Colorado Comprehensive Cancer Center,

Abstract

Risk of brain metastases in metastatic non-small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from three randomized clinical trials involving first-line atezolizumab treatment.

Org: Fudan University Shanghai Cancer Center, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,

Abstract

A phase I/II study to evaluate the safety, pharmacodynamics, and efficacy of entinostat in combination with atezolizumab and bevacizumab in patients with renal cell carcinoma.

Org: University at Buffalo Jacobs School of Medicine and Biomedical Sciences, University of Pennsylvania-Abramson Cancer Center, Ohio State University Comprehensive Canvcer Hospital, Indiana University – Purdue University Indianapolis, Abramson Cancer Center, University of Pennsylvania,

Abstract

A randomized, open-label, phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF-S633/DANTE trial, a trial of AIO in collaboration with SAKK.

Org: Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest, Krankenhaus Nordwest, University Cancer Center Frankfurt and Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Klinikum rechts der Isar, Technische Universität München, Charité–Universitätsmedizin Berlin,

Abstract

MyTACTIC: Afficacy and safety of atezolizumab (atezo) + chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR).

Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, OneOncology, Inc., New York Cancer and Blood Specialists,

Abstract

Novel STK11 differentiation phenotype classifier STK11-DPC: Immunosuppressive tumor microenvironment (TME) and response to immune checkpoint blockade (ICB) in STK11-deficient NSCLC.

Org: The James Cancer Hospital and Solove Research Institute, Ohio State University Comprehensive Cancer Center, Ohio State University Comprehensive Canvcer Hospital, The Ohio State University - James Cancer Hospital, The Ohio State University Wexner Medical Center,

Abstract

Cost-effectiveness analysis of later-line therapies for metastatic colorectal cancer (mCRC) based on a novel methodology of network meta-analysis (NMA) of survival curves.

Org: The University of Arizona, Tucson, AZ, University of Arizona Cancer Center, University of Arizona, University of Arizona of Pharmacy, Department of Pharmacy Practice and Science,

Abstract

Individual patient-level data validation of surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma: Post-hoc analysis of IMbrave150 and real-world observations.

Org: UT Southwestern Medical Center, University of Texas Southwestern Medical Center, Taipei Veterans General Hospital,

Abstract

Immune landscape of patients with metastatic non-clear cell renal cell carcinoma (nccRCC) treated with atezolizumab plus bevacizumab.

Org: Dana-Farber Cancer Institute, Dana-Farber Cancer Institute and Harvard Medical School, Brigham and Women's Hospital/Massachusetts General Hospital, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, Department of Medical Oncology, Gustave Roussy,

Abstract

An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma.

Org: Cleveland Clinic Taussig Cancer Instititute, Beth Israel Deaconess Medical Center, Mayo Clinic, Replimune,

Abstract

Exploring the prognostic and predictive impact of genomic loss of heterozygosity (LOH) in patients with metastatic colorectal cancer (mCRC).

Org: Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana and Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, Charité Universitätsmedizin Berlin, Berlin, Germany, Oncology Unit 1, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy, Department of Medical Oncology, University Campus Biomedico, Roma, Italy, Division of Clinical Pharmacology and Oncology, Department of Health Sciences, School of Psychology, University of Florence, Florence, Italy, University of Pisa, Pisa, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS Padua, Padua, Italy, U.O.C. Oncologia Medica, Presidio Ospedaliero Livorno, Livorno, Italy, Hämatologisch Onkologische Praxis Eppendorf (HOPE) and Universitäres Cancer Center Hamburg, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, Department of Oncology, Istituto Scientifico San Raffaele IRCSS, Milan, Italy, CdC Poliambulanza, Brescia, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS, Padua, Italy, IRCSS-CRO Aviano, Department of Clinical Oncology, Aviano, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Martin Luther University, Halle, Germany, Azienda Ospedaliera Universitaria Pisana, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa & Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, University of Pisa, Pisa, Italy, University Campus Biomedico,

Abstract

Molecular subtypes from comprehensive clustering from multi-omics dataset to predict the therapeutic efficacy of immunotherapeutic agent-based treatments in advanced hepatocellular carcinoma.

Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, CHA Bundang Medical Center, CHA University School of Medicine, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Medical Oncology Group,

Abstract

Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study.

Org: Kindai University Faculty of Medicine, Osaka-Sayama, Japan, Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Hokkaido, Japan, Musashino Red Cross Hospital, Chiba University, Graduate School of Medicine, The University of Tokyo,

Abstract

Durvalumab and tremelimumab for hepatocellular carcinoma in patients listed for a liver transplant.

Org: University of Cincinnati College of Medicine, Cincinnati Children s Hospital Medical Center, University of Cincinnati Medical Center,

Abstract

Circulating tumor DNA (ctDNA) monitoring to inform maintenance outcomes in patients (pts) with advanced NSCLC treated with induction atezolizumab+carboplatin+nab-paclitaxel (A+CnP).

Org: H. Lee Moffitt Cancer Center and Research Institute, Foundation Medicine, Inc., Cambridge, MA, Genentech Inc., Natera, Inc., Genentech,

Abstract

A phase II multi-cohort single-arm study of tiragolumab with atezolizumab plus bevacizumab in previously treated advanced non-squamous non–small-cell lung cancer.

Org: Georgetown University Medical School, Patient Advocate, Johns Hopkins University School of Medicine, Hackensack University Medical Center,

Abstract

Real-world multicentre analysis of patients with hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (A+B): Efficacy, esophagogastroduodenoscopy (EGD) uptake and bleeding complications.

Org: Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Tom Baker Cancer Centre,

Abstract

An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab and bevacizumab therapy in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.

Org: Mayo Clinic, Scottsdale, AZ, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Hospital, Baltimore, MD,

Abstract

SHR-1701 in combination with platinum-based chemotherapy and BP102 (a bevacizumab biosimilar) for persistent, recurrent, or metastatic cervical cancer: Data from a phase 1b/3 study.

Org: Sun Yat-sen University Cancer Center Gansu Hospital, First Affiliated Hospital of Gannan Medical University, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, The Second People's Hospital of Yibin City, Fudan University Shanghai Cancer Center,

Abstract

Assessing tumor-infiltrating immune cells and outcomes with cisplatin- versus carboplatin-based treatment in advanced urothelial cancer (UC): Survival analysis of three platinum-treated UC cohorts.

Org: Medical University of Lodz, Lodz, Poland, PSMAR Hospital del Mar Medical Research Institute (IMIM), Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Dana-Farber Cancer Institute,

Abstract

Geographical and baseline clinical characteristics of participants enrolled in hepatocellular carcinoma (HCC) trials: Analysis of US FDA approvals.

Org: FDA/CDER, U.S. Food and Drug Administration, US Food and Drug Administration, Oncology Center of Excellence, Office of New Drugs,

Abstract

Association of nuclear shape in the tumor epithelium with response to atezolizumab in NSCLC.

Org: Genentech, South San Francisco, CanSino Biologics, Genentech Inc., Rancho BioSciences LLC,

Abstract

TROP2 expression and response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.

Org: Early Phase Trials Unit, Institut Bergonié and University of Bordeaux, Bordeaux, France, Institut Bergonié, University of Bordeaux, Bergonié Institute, ImmuSmol,

Abstract

A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.

Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Shanghai Pulmonary Hospital, Shanghai, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, The Second Hospital Affiliated to Air Force Medical University, Qilu Pharmaceutical,

Abstract

AFT-50 EndoMAP: A phase IB/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer.

Org: Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, University of Chicago, Chicago, IL,

Abstract

Baseline autoantibody profiling in patients with NSCLC with pre-existing autoimmune diseases or who had received prior anti-PD-1 therapy before enrolling in the TAIL study.

Org: Complejo Hospitalario Universitario Insular-Materno Infantil, Oncimmune Germany GmbH, Rochester Regional Health System, F. Hoffmann-La Roche AG, Genentech Inc.,

Abstract

Dares: A phase II trial of durvalumab and ablative radiation in extensive stage small cell lung cancer.

Org: University of Chicago Medical Center, Chicago, IL, University of Kansas Medical Center, Department of Biostatistics & Data Science, University of Kansas Medical Center (KUMC), Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, University of Chicago,

Abstract

Effect of DUAL pharmacological blockade of AURKA and PD-L1 pathways on plasticity and metastasis for triple negative breast cancer.

Org: Mayo Clinic, Rochester Regional Health System, MN,

Abstract

Incidence of venous thromboembolism with immune checkpoint inhibitors in a community setting: A single-center retrospective study.

Org: Saint Vincent Hospital Cancer Center Green Bay, Saint Vincent Cancer and Wellness Center,

Abstract

A phase 2 study of an anti–PD-L1 antibody (atezolizumab) in dedifferentiated chondrosarcoma.

Org: Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO, University of Texas MD Anderson Cancer Center, Houston, TX, Vanderbilt University Medical Center, Nashville, TN, University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA,

Abstract

A gut microbiota rheostat to forecast response to PDL1-VEGF blockade in mesothelioma.

Org: University of Leicester and Leicester University Hospitals, Leicester University Hospitals, Harry Perkins Institute of Medical Research, The University of Western Australia Centre for Medical Research, Leicester Royal Infirmary,

Abstract

Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).

Org: Mayo Clinic, Alliance Statistics and Data Management Center, Mayo Clinic Arizona, Phoenix, AZ, University of Pittsburgh Medical Center, Johns Hopkins Medicine,

Abstract

Investigating the novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager, AFM24, to leverage the innate immune system: Interim results from the colorectal cancer (CRC) cohort.

Org: INCLIVA-Biomedical Research Institute, Biomedical Research Institute INCLIVA, Hospital Clínico Universitario-INCLIVIA, Valencia, Spain, University of Valencia, Affimed Inc.,

Abstract

Phase 1/2 study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1 or SMARCA4 deficient tumors.

Org: Pediatric Oncology Branch, Clinical Center National Institutes of Health, NCI, Nihon Medi-Physics, National Cancer Institute, Vilnius, Lithuania, Institute for Clinical and Translational Research, Baylor College of Medicine,

Abstract

Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.

Org: Hôpitaux Nord-Ouest, Univ Rouen Normandie, LITIS Lab QuantIF team EA4108, CHU Rouen, Inserm CIC-CRB 1404,

Abstract

Evaluation of a risk-sharing agreement for atezolizumab treatment in second- and third-line NSCLC patients: A strategy in order to improve access in low income countries.

Org: Instituto Nacional de Cancerologia, Mexico City, DF, Mexico, Instituto Nacional De Cancerologia - Mexico, HS Estudios Farmacoeconomicos, EMS,

Abstract

Using real-world evidence (RWE) in regulatory decision making: A study of 6 oncology approvals with RWE included in the product label.

Org: Bayer HealthCare Pharmaceuticals Inc., Bayer, Xcenda, Xcenda LLC, Bayer Corporation,

Abstract

Reveal irAE by analysis of 197,921 claim-based prescriptions.

Org: AESOP Technology Inc.,

Abstract

Predictors of response in advanced colorectal cancer (CRC) patients treated with immune-checkpoint inhibitors (ICI).

Org: The Ohio State University College of Medicine, Ohio State University Wexner Medical Center, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, James Cancer Hospital and Solove Research Institute and The Ohio State University Wexner Medical Center, Wexner Medical Center and The James Cancer Hospital, Ohio State University,

Abstract

Safety of checkpoint inhibitors in older patients with genitourinary cancers.

Org: University of Florida/UF Health Cancer Center, University of Florida Department of Health Outcomes and Biomedical Informatics,

Abstract

Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Cleveland Clinic Taussig Cancer Instititute, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University,

Abstract

Toxicity profile, palliative care and hospice utilization of geriatric patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in the Veteran Health Administration.

Org: South Texas Veterans Health Care System, University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center-San Antonio, Audie L. Murphy Memorial Veterans Hospital, University of Texas Science Center at San Antonio,

Abstract

Efficacy and safety in unresectable hepatocellular carcinoma using atezolizumab plus bevacizumab in later-line: A retrospective analysis of real-world evidence.

Org: Senior Department of Hepatology, the 5th Medical Center of the PLA General Hospital, Beijing, China, Peking University 302 Clinical Medical School, Beijing, China, The Fifth School of Clinical Medicine, Anhui Medical University, Hefei, China, Senior Department of Oncology, the 5th Medical Center of the PLA General Hospital, Beijing, China,

Abstract

Novel machine learning algorithm to predict response to immunotherapy in patients with small cell and non-small cell lung cancer.

Org: GKT School of Medicine, King's College London, Curenetics Ltd, Imperial College London, School of Physics, Engineering & Computer Science,

Abstract

Obesity, dyslipidemia, and diabetes as determinants of response to immune checkpoint inhibitors in non-small cell lung cancer.

Org: Beth Israel Deaconess Medical Center, Roswell Park Comprehensive Cancer Center, Mount Auburn Hospital, Harvard Medical School, Lahey Hospital and Medical Center, Burlington, MA,

Abstract

Hemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: A pharmacovigilance study from FDA Database.

Org: Rochester General Hospital, Rochester, NY, Patan Academy of Health Sciences, Kathmandu, Nepal, Kathmandu, Nepal, University at Buffalo Jacobs School of Medicine and Biomedical Sciences,

Abstract

Reconsidering the cutoff between sensitive and refractory relapses in extensive-stage small cell lung cancer in the era of immunotherapy.

Org: Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan, Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Respiratory Medicine, Kitasato University School of Medicine, Kanagawa, Japan, Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan, Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan,

Abstract

Real world data on immunotherapeutic outcomes in solid tumours.

Org: The Brunei Cancer Center, The Brunei Cancer Centre,

Abstract

Use of tumor mutational burden as a predictive marker of response to immuno-oncology agents: Initial experience at an academic center in Venezuela.

Org: Centro Medico Docente La Trinidad, Caracas, Venezuela (Bolivarian Republic of), Beth Israel Deaconess Medical Center, Boston, MA, Advocate Aurora Health, Chicago, IL, Centro Medico Docente la Trinidad, Caracas, Miranda, Venezuela (Bolivarian Republic of),

Abstract

A functional immuno-oncology (IO) assay to assess patient response to immunotherapeutics in metastatic disease.

Org: Xilis, Inc., Xilis Inc., Xilis,

Abstract

Adrenal insufficiency in patients on immune checkpoint inhibitors: An All of Us Data study.

Org: Harlem Hospital Center, New York Oncology Hematology PC,

Abstract

Atezolizumab plus bevacizumab combined with transarterial embolization plus hepatic arterial infusion-chemotherapy for unresectable hepatocellular carcinoma with a diameter larger than 8 cm: A retrospective study.

Org: Department of Interventional Radiology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, The First Affiliated Hospital of Sun Yat-sen University, Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center Gansu Hospital, Sun Yat-sen University State Key Laboratory of Oncology in South China,

Abstract

Efficacy and safety analysis of immune checkpoint inhibitors plus angiogenesis inhibitors for treatment of advanced driver-negative NSCLC in elderly patients: A retrospective study.

Org: The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Kintor Pharmaceutical, China National Biotec Group,

Abstract

The role of immunotherapy in stage III large cell neuroendocrine carcinoma of the lung (LCNEC): A retrospective NCDB analysis.

Org: Louisiana State University (Shreveport) Program at Feist-Weiller Cancer Center, Shreveport, LA,

Abstract

Real world outcomes of trilaciclib in ES-SCLC.

Org: Roswell Park Comprehensive Cancer Center, University at Buffalo School of Pharmacy and Pharmaceutical Sciences,

Abstract

Ustekinumab for the treatment of immune related cutaneous adverse events (ircAEs).

Org: Memorial Sloan Kettering Cancer Center,

Abstract

Outcomes for immuno-chemotherapy based treatment in patients with poorly differentiated extrapulmonary neuroendocrine carcinoma.

Org: University of Arizona Cancer Center, University of Arizona College of Medicine - Tucson, The University of Arizona Cancer Center, University of Arizona Department of Neuroscience,

Abstract

Efficacy of checkpoint inhibitors in hospitalized patients with cancer.

Org: Rutgers Health Community Medical Center, Monmouth Medical Center, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,

Abstract

Anti-PD1 antibody pucotenlimab in combination with bevacizumab or lenvatinib in a phase II study for the treatment of advanced hepatocellular carcinoma (aHCC).

Org: Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, The central hospital of lishui city, Lishui, China, Department of Gastroenterology,Harbin Medical University Cancer Hospital, Harbin, China, Hunan Provincial People's Hospital, Changsha, China,

Abstract

Immune therapy related adverse events in metastatic non-small cell lung carcinoma patients at a rural academic center.

Org: Brody School of Medicine at East Carolina University, ECU Health,

Abstract

Predictors of long-term progression-free survival (PFS) in niraparib-treated patients (pts) from the PRIMA/ENGOT-OV26/GOG-3012 study.

Org: Medical University of South Carolina Hollings Cancer Center, Institut Català d’Oncologia L’Hospitalet de Llobregat, Hospital Duran i Reynals, IDIBELL, Grupo Español de Investigación en Cáncer de Ovario (GEICO),

Abstract

Anti-drug antibodies related to CTLA-4, PD-1, or PD-L1 inhibitors across tumour types: A systematic review.

Org: Imperial College, University Medical Center Mainz, Mtech Access, Eisai, UCLA Medical Center,

Abstract

Introducing yttrium-90 radioembolization to atezolizumab and bevacizumab regimen for intermediate and advanced stage hepatocellular carcinoma: A preliminary report of safety and effectiveness.

Org: University of Chicago Medical Center, Chicago, IL, Chicago, IL, Ascension Providence Hospital, Southfield, MI, University of Chicago,

Abstract

How comparable are outcomes for approved PD-1/PD-L1 checkpoint inhibitors (CPI)? A model-informed drug development approach to answer the question.

Org: Gilead Sciences, Inc., Foster City, CA, Certara, Inc., Princeton, NJ, Gilead Sciences Inc.,

Abstract

Cost-utility analyses of later-line treatments for metastatic colorectal cancer (mCRC) by network meta-analysis (NMA) approach: Conventional constant hazard ratio vs novel survival curves methodologies.

Org: University of Arizona, University of Arizona Cancer Center, University of Arizona of Pharmacy, Department of Pharmacy Practice and Science,

Abstract

Real-world safety and effectiveness of MVASI in metastatic colorectal cancer patients in Canada.

Org: IQVIA, Global Database Studies, Mölndal, Sweden, Amgen Canada Inc., Mississauga, ON, Canada, Amgen, Shanghai, China,

Abstract

Comparative efficacy of later-line therapies for metastatic colorectal cancer (mCRC) using novel methods for patient survival data reconstruction and network meta-analysis (NMA) of survival curves.

Org: University of Arizona of Pharmacy, Department of Pharmacy Practice and Science, University of Arizona Cancer Center, The University of Arizona, Tucson, AZ, University of Arizona,

Abstract

Treatment patterns post atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: Real-world analysis at Veterans Health Administration comparing lenvatinib vs. sorafenib.

Org: Univeristy of Texas Health Science Center San Antonio, San Antonio, TX, University of Texas Health Science Center at San Antonio, San Anonio, TX, The University of Texas Health Science Center-San Antonio,

Abstract

Real-world experience with atezolizumab plus bevacizumab in the management of non-resectable hepatocellular carcinoma refractory to first-line systemic therapy: Review of literature.

Org: Feist-Weiller Cancer Center at LSUHSC-Shreveport, LSU Health Shreveport, Ochsner LSU Health, Merit health, LSUHSC-S,

Abstract

COVID-19 induced remission of biliary and renal cell carcinomas.

Org: University of Pittsburgh, Pittsburgh, PA, Pittsburgh, PA,

Abstract

Real-world experience and outcomes of immune-checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC).

Org: Ohio State University Comprehensive Canvcer Hospital, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, The Ohio State University Wexner Medical Center, Ohio State University Wexner Medical Center,

Abstract

The evolution of treatment patterns in patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) and clinical outcomes: Results of a longitudinal observational cohort study in England.

Org: Merck, Health Data Insight CIC, NHS Digital,

Abstract

Real-world analysis of ICI efficacy in ES-SCLC patients with and without brain metastases: A call for inclusion in clinical trials.

Org: Dartmouth-Hitchcock Medical Center, Lebanon, NH, NHS Greater Glasgow and Clyde, Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center,

Abstract

Characterizing immune-genomic signatures associated with response to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC).

Org: Cleveland Clinic Lerner College of Medicine, John D. Dingell VA Hospital, Cleveland Clinic Taussig Cancer Instititute, Cleveland Clinic Lerner Research Institute, Cleveland, OH,

Abstract

Evolution of cancer treatment costs in the last 36 months in a self-funded health care in Brazil.

Org: CAPESESP,

Abstract

Eosinophil count and immune-related adverse events (irAEs) as predictive biomarkers of survival in patients with NSCLC treated with ICIs.

Org: Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, Careggi University Hospital, Department of Experimental and Clinical Medicine - Careggi University Hospital, Largo Brambilla, University of Florence, AOUC,

Abstract

Real world utilization and outcomes of immunotherapy regimens in metastatic castration resistant prostate cancer (mCRPC).

Org: Tisch Cancer Institute, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY,

Abstract

“Interchangeability” of anti-PD1 antibodies in patients (pts) with metastatic melanoma (mM).

Org: Moskovskii Mnogoprofilnyi Klinicheskii Tcentr "Kommunarka" Departamenta Zdravoohraneniia Goroda Moskvy, N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, N.N. Blokhin NMRCO, N.N. Petrov Institute of Oncology, Kommunarka Moscow City Clinical Center,

Abstract

Comparison of atezolizumab monotherapy to docetaxel with and without ramucirumab in patients with advanced non-small-cell lung cancer who received prior immunotherapy.

Org: Mayo Clinic Florida, Mayo Clinic,

Abstract

Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study).

Org: Centre François Baclesse, GINECO-Centre Jean Perrin, Clermont-Ferrand, France, Centre Léon Bérard, Hospital Universitario Reina Sofia de Cordoba, GEICO,

Abstract

Atezolizumab + intravesical BCG (bacillus Calmette-Guerin) upfront combination in high risk non–muscle- invasive bladder cancer (NMIBC) patients: Safety interim report of BladderGATE phase I-II study.

Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital Universitario 12 de Octubre, Unidad de Oncología Molecular CIEMAT, Unidad de Oncologia Molecular CIEMAT, Urology Department,

Abstract

Prevalence of EGFR and PDL1 testing in a population-based lung cancer surgical resection cohort from 2018-2022.

Org: University of Memphis, School of Public Health, Fudan University, Memphis, TN, Baptist Cancer Center, Memphis, TN, Multidisciplinary Thoracic Oncology Department,

Product

Atezolizumab + Bevacizumab

Abstract

Multi-omics analysis of atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma.

Org: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China, Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China, Beijing, China, Geneplus-Beijing, Beijing 102205, Beijing, China, Fujian Cancer Hospital, Fuzhou, China, Geneplus-Beijing, Beijing, China, Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing, China,

Product

Atezolizumab

Product

Bevacizumab

Product

PC + bevacizumab + durvalumab + olaparib

Product

nivolumab + bevacizumab

Product

CCNU + Bevacizumab

Product

AFM24 + Atezolizumab

Product

placebo + atezolizumab + cisplatin/carboplatin + etoposide

Product

Atezolizumab + UCPVax

Product

Atezolizumab with neoadjuvant chemoradiotherapy

Product

atezolizumab + EC followed by atezolizumab + anlotinib

Product

luveltamab tazevibulin + bevacizumab

Product

BNVax + BA + Anktiva

Product

anti-PD-1 or anti-PD-L1 monotherapy

Product

Standard-of-care therapies followed by PARPi or bevacizumab for maintenance

Product

atezolizumab, ADT, ARPI, SBRT

Product

ompenaclid + FOLFIRI/BEV

Product

Pazopanib alternating with Bevacizumab

Product

Bevacizumab + nab-paclitaxel

Product

dostarlimab + carboplatin-paclitaxel

Abstract

Association of docetaxel efficacy with cancer gene mutation status in patients with metastatic non-small-cell lung cancer who progressed on platinum doublets and immunotherapy.

Org: Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, Mayo Clinic, Jacksonville, FL, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, University of Texas MD Anderson Cancer Center, Houston, TX,

Product

Atezolizumab + Split-dose Cisplatin + Gemcitabine

Product

FOLFOX plus bevacizumab followed by chemoradiotherapy

Product

tislelizumab, bevacizumab, CAPOX

Product

Neoadjuvant immunotherapy-driven bladder preservation

Product

Trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV)

Product

Tislelizumab + Bevacizumab + Oxaliplatin + Capecitabine

Product

anti PD-1 antibodies

Product

Atezolizumab + chemoradiotherapy

Product

PD1/L1 antibody

Product

atezolizumab/bevacizumab

Product

dostarlimab+carboplatin-paclitaxel

Product

FTD/TPI plus bevacizumab

Product

FTD/TPI + bevacizumab

Product

TECENTRIQ + Bevacizumab + Paclitaxel + Carboplatin

Product

anti PD-1 therapy

Product

SOF10 + atezolizumab

Product

Atezolizumab + Carboplatin + Pemetrexed + Bevacizumab

Product

Cabozantinib + Atezolizumab

Product

Atezolizumab + Cobimetinib + Vemurafenib

Product

nivolumab and bevacizumab

Product

cobolimab + dostarlimab

Product

gemcitabine + carboplatin + bevacizumab

Product

paclitaxel, carboplatin, bevacizumab, pamiparib

Product

Atezolizumab, Bevacizumab, Carboplatin, (nab-)Paclitaxel

Product

carboplatin plus paclitaxel with bevacizumab

Product

TPI 287 + bevacizumab

Product

atezolizumab + bevacizumab

Product

Bevacizumab, then Lomustine + Bevacizumab

Product

Bevacizumab monotherapy

Abstract

An open-label, multicenter, adaptive, phase Ib/II study of QL1706 or QL1604 plus bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma.

Org: Department of Abdominal Oncology, West China Hospital of Sichuan University, Chengdu, China, Department of Gastroenterology Second Ward, Harbin Medical University Cancer Hospital, Harbin, China, Department of Intervention,Hunan Cancer Hosptial, Changsha, China, Liver Tumor Center, Nanfang Hospital Southern Medical University, Guangzhou, China, Phase I Clinical Research Room,Nanfang Hospital Southern Medical University, Guangzhou, China,

Product

Bevacizumab, Eribulin, Oxaliplatin

Product

Bevacizumab plus chemotherapy

Product

Erlotinib + Bevacizumab

Product

Immune checkpoint inhibitor therapy (ICT)

Product

Bevacizumab + Fotemustine

Product

IBI305